U.S. patent application number 13/744627 was filed with the patent office on 2013-06-06 for antibody to human zcyto-10 polypeptide.
This patent application is currently assigned to ZYMOGENETICS, INC.. The applicant listed for this patent is ZymoGenetics, Inc.. Invention is credited to Darrell C. CONKLIN, Angelika GROSSMANN, Betty A. HALDEMAN.
Application Number | 20130142801 13/744627 |
Document ID | / |
Family ID | 46279449 |
Filed Date | 2013-06-06 |
United States Patent
Application |
20130142801 |
Kind Code |
A1 |
CONKLIN; Darrell C. ; et
al. |
June 6, 2013 |
ANTIBODY TO HUMAN ZCYTO-10 POLYPEPTIDE
Abstract
Antibodies that which specifically bind to mammalian
cytokine-like polypeptide, called Zcyto10, are described. The
antibodies include monoclonal antibodies and those that where the
antibody is an antigen-binding fragment. Zcyto10 is useful for
promoting the healing of wounds and for stimulating the
proliferation of platelets.
Inventors: |
CONKLIN; Darrell C.;
(Seattle, WA) ; HALDEMAN; Betty A.; (Seattle,
WA) ; GROSSMANN; Angelika; (Seattle, WA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ZymoGenetics, Inc.; |
Seattle |
WA |
US |
|
|
Assignee: |
ZYMOGENETICS, INC.
Seattle
WA
|
Family ID: |
46279449 |
Appl. No.: |
13/744627 |
Filed: |
January 18, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13361638 |
Jan 30, 2012 |
8378079 |
|
|
13744627 |
|
|
|
|
12891586 |
Sep 27, 2010 |
8124739 |
|
|
13361638 |
|
|
|
|
12552239 |
Sep 1, 2009 |
7829089 |
|
|
12891586 |
|
|
|
|
12111798 |
Apr 29, 2008 |
7601830 |
|
|
12552239 |
|
|
|
|
11458910 |
Jul 20, 2006 |
|
|
|
12111798 |
|
|
|
|
10789129 |
Feb 27, 2004 |
7119191 |
|
|
11458910 |
|
|
|
|
10413661 |
Apr 15, 2003 |
7115714 |
|
|
10789129 |
|
|
|
|
09313458 |
May 17, 1999 |
6576743 |
|
|
10413661 |
|
|
|
|
09199586 |
Nov 25, 1998 |
|
|
|
09313458 |
|
|
|
|
60066597 |
Nov 26, 1997 |
|
|
|
Current U.S.
Class: |
424/139.1 |
Current CPC
Class: |
A61K 39/3955 20130101;
C07K 14/52 20130101; A61P 43/00 20180101 |
Class at
Publication: |
424/139.1 |
International
Class: |
A61K 39/395 20060101
A61K039/395 |
Claims
1-8. (canceled)
9. A method of treating a subject diagnosed with a disease of the
tracheobronchial tract, comprising administering an antibody, or
binding fragment thereof, which binds to Mammalian Cytokine-like
polypeptide-10 (Zcyto10) (SEQ ID NO: 2), such that the subject is
treated.
10. The method of claim 9, wherein the disease is selected from
asthma and bronchitis.
11. The method of claim 9, wherein the antibody is a polyclonal or
a monoclonal antibody.
12. The method of claim 9, wherein the fragment is an F(ab').sub.2
fragment.
13. The method of claim 9, wherein the fragment is an Fab
fragment.
14. The method of claim 9, wherein the antibody or fragment binds
to the amino acid residues selected from the group consisting of
(a) amino acid residues 25 to 176 of SEQ ID NO:2, (b) amino acid
residues 35 to 49 of SEQ ID NO:2, (c) amino acid residues 57 to 71
of SEQ ID NO:2, (d) amino acid residues 91 to 105 of SEQ ID NO:2,
(e) amino acid residues 112 to 126 of SEQ ID NO:2, and (f) amino
acid residues 158 to 172 of SEQ ID NO:2.
15. The method of claim 9, wherein the antibody or fragment binds
to an amino acid sequence selected from the group consisting of (a)
SEQ ID NO:12, (b) SEQ ID NO:26, (c) SEQ ID NO:14, (d) SEQ ID NO:15,
(e) SEQ ID NO:16, and (f) SEQ ID NO:17.
16. The method of claim 9, wherein the antibody is a monoclonal
antibody.
17. The method of claim 9, wherein the disease is asthma.
18. The method of claim 9, wherein the disease is bronchitis.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 12/891,586, filed Sep. 27, 2010, which is a continuation
of U.S. patent application Ser. No. 12/552,239 filed Sep. 1, 2009,
now U.S. Pat. No. 7,829,089, which is a divisional of U.S. patent
application Ser. No. 12/111,798, filed Apr. 29, 2008, now U.S. Pat.
No. 7,601,830, which is a continuation of U.S. patent application
Ser. No. 11/458,910, filed Jul. 20, 2006, now abandoned, which is a
divisional of U.S. patent application Ser. No. 10/789,129, filed
Feb. 27, 2004, now U.S. Pat. No. 7,119,191, which is a continuation
of U.S. patent application Ser. No. 10/413,661, filed Apr. 15,
2003, now U.S. Pat. No. 7,115,714, which is a continuation of U.S.
patent application Ser. No. 09/313,458, filed May 17, 1999, now
U.S. Pat. No. 6,576,743, which is a continuation-in-part of U.S.
patent application Ser. No. 09/199,586, filed Nov. 25, 1998, which
claims the benefit of U.S. Provisional Application No. 60/066,597,
filed Nov. 26, 1997, all of which are herein incorporated by
reference in their entirety.
BACKGROUND
[0002] Proliferation and differentiation of cells of multicellular
organisms are controlled by hormones and polypeptide growth
factors. These diffusable molecules allow cells to communicate with
each other and act in concert to form cells and organs, and to
repair and regenerate damaged tissue. Examples of hormones and
growth factors include the steroid hormones (e.g. estrogen,
testosterone), parathyroid hormone, follicle stimulating hormone,
the interleukins, platelet derived growth factor (PDGF), epidermal
growth factor (EGF), granulocyte-macrophage colony stimulating
factor (GM-CSF), erythropoietin (EPO) and calcitonin.
[0003] Hormones and growth factors influence cellular metabolism by
binding to proteins. Proteins may be integral membrane proteins
that are linked to signaling pathways within the cell, such as
second messenger systems. Other classes of proteins are soluble
molecules.
[0004] Of particular interest are cytokines, molecules that promote
the proliferation and/or differentiation of cells. Examples of
cytokines include erythropoietin (EPO), which stimulates the
development of red blood cells; thrombopoietin (TPO), which
stimulates development of cells of the megakaryocyte lineage; and
granulocyte-colony stimulating factor (G-CSF), which stimulates
development of neutrophils. These cytokines are useful in restoring
normal blood cell levels in patients suffering from anemia or
receiving chemotherapy for cancer. The demonstrated in vivo
activities of these cytokines illustrate the enormous clinical
potential of, and need for, other cytokines, cytokine agonists, and
cytokine antagonists.
SUMMARY
[0005] The present invention addresses this need by providing an
isolated antibody which selectively binds to an amino acid sequence
consisting of at least nine amino acids residues of a polypeptide
consisting of the amino acid sequence set forth in SEQ ID NO: 4. In
one embodiment, the antibody binds to an amino acid sequence of a
polypeptide, where the sequence is selected from the group
consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID
NO:28 and SEQ ID NO:29. In other embodiments, the antibody binds to
an amino acid sequence that is at least fifteen or 30 amino acid
residues. In another embodiment, the antibody of the claimed
invention is a monoclonal antibody. In another embodiment, the
antibody binds to the polypeptide with a K.sub.a of greater than
10.sup.7/M. In another embodiment, the antibody is an
antigen-binding fragment. In other embodiments of the claimed
invention, the antigen-binding fragment is an Fab or
F(ab').sub.2.
[0006] Mouse Zcyto10 is also a polypeptide comprised of 176 amino
acid residues as defined by SEQ ID NOs: 18 and 19. Mouse Zcyto10
has a signal sequence extending from amino acid residue 1, a
methionine, extending to and including amino acid residue 24, a
glycine of SEQ ID NO:19. Thus, the mature mouse Zcyto10 extends
from amino acid residue 25, a leucine, to and including amino acid
residue 176 a leucine of SEQ ID NO:19, also defined by SEQ ID
NO:20. Another active variant is believed to extend from amino acid
33, a cysteine, through amino acid 176, of SEQ ID NO:19. This
variant is also defined by SEQ ID NO:25. Also described is the
polypeptide further comprising an affinity tag.
[0007] A variant of mouse Zcyto10 is defined by SEQ ID NOs: 33 and
34. This variant is 154 amino acid residues in length and has a
signal sequence extending from amino acid residue 1, a methionine,
to and including amino acid residue 24, a glycine, of SEQ ID NO:34.
Thus, the mature sequence extends from amino acid residue 25, a
leucine, to and including amino acid residue 154, a leucine, of SEQ
ID NO:34. The mature sequence is also defined by SEQ ID NO:35.
[0008] Within the disclosure is description of an expression vector
comprising (a) a transcription promoter; (b) a DNA segment encoding
Zcyto10 polypeptide, and (c) a transcription terminator, wherein
the promoter, DNA segment, and terminator are operably linked.
[0009] Also described is a cultured eukaryotic or prokaryotic cell
into which has been introduced an expression vector as disclosed
above, wherein said cell expresses a polypeptide encoded by the DNA
segment.
[0010] The disclosure further describes a chimeric polypeptide
consisting essentially of a first portion and a second portion
joined by a peptide bond. The first portion of the chimeric
polypeptide consists essentially of (a) a Zcyto10 polypeptide as
shown in SEQ ID NO: 2 (b) allelic variants of SEQ ID NO:2, SEQ ID
NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ
ID NO:25, SEQ ID NO:26 SEQ ID NO:34 or SEQ ID NO:35; and (c)
protein polypeptides that are at least 90% identical to (a) or (b).
The second portion of the chimeric polypeptide consists essentially
of another polypeptide such as an affinity tag. Within one
embodiment the affinity tag is an immunoglobulin F.sub.C
polypeptide. The description includes expression vectors encoding
the chimeric polypeptides and host cells transfected to produce the
chimeric polypeptides.
[0011] Within the disclosure is also described an antibody that
specifically binds to a Zcyto10 polypeptide as disclosed above, and
also an anti-idiotypic antibody which neutralizes the antibody to a
Zcyto10 polypeptide.
[0012] Within the disclosure includes description of a
pharmaceutical composition comprising purified Zcyto10 polypeptide
in combination with a pharmaceutically acceptable vehicle. Such
compositions may be useful for modulating of cell proliferation,
cell differentiation or cytokine production in the prevention or
treatment of conditions characterized by improper cell
proliferation, cell differentiation or cytokine production, as are
further discussed herein. More specifically, Zcyto10 polypeptide
may be useful in the prevention or treatment of autoimmune diseases
by inhibiting a cellular immune response. Autoimmune diseases which
may be amenable to Zcyto10 treatment include IDDM, multiple
sclerosis, rheumatoid arthritis and the like. Also, Zcyto10
polypeptides of the present invention may be useful in inhibiting
cancer cell growth or proliferation.
[0013] Zcyto10 polypeptides disclosed herein may also stimulate the
immune system to better combat microbial or viral infections. In
particular, Zcyto10 can be administered systemically to increase
platelet production by an individual. Moreover, Zcyto10
polypeptides of the present invention may be used in
trachea-specific or tracheobronchial-specific applications, such as
in the maintenance or wound repair of the tracheobronchial
epithelium or cells underlying the same, in regulating mucous
production or mucocilary clearance of debris or in treatment of
asthma, bronchitis or other diseases of the tracheobronchial tract.
It may also enhance wound healing and promote regeneration of
affected tissues which may be especially useful in the treatment of
periodontal disease. Furthermore, Zcyto10 polypeptides can be used
to treat skin conditions such as psoriasis, eczema and dry skin in
general.
[0014] Additional embodiments disclosed relate to a peptide or
polypeptide which has the amino acid sequence of an epitope-bearing
portion of a Zcyto10 polypeptide having an amino acid sequence
described above. Peptides or polypeptides having the amino acid
sequence of an epitope-bearing portion of a Zcyto10 polypeptide of
the present invention include portions of such polypeptides with at
least nine, preferably at least 15 and more preferably at least 30
to 50 amino acids, although epitope-bearing polypeptides of any
length up to and including the entire amino acid sequence of a
polypeptide of the present invention described above are also
included in the present invention. These polypeptides are also
fused to another polypeptide or carrier molecule. Such epitope
variants include but are not limited to SEQ ID NOs: 25-32.
Antibodies produced from these epitope-bearing portions of Zcyto10
can be used in purifying Zcyto10 from cell culture medium.
[0015] Within the disclosure includes description of an antisense
molecule comprising a polynucleotide complementary to a segment of
a nucleic acid sequence of SEQ ID. NO:1. In certain embodiments,
the segment comprises nucleotides 117 to 572 of SEQ ID. NO:1.
[0016] Within is disclosed a pharmaceutical composition comprising
a polypeptide selected from the group consisting of SEQ ID. NO:2,
SEQ ID. NO:4, SEQ ID. NO:12, SEQ ID.
[0017] NO:13, SEQ ID. NO:19, SEQ ID. NO:20, SEQ ID. NO:25, SEQ ID.
NO:26, SEQ ID. NO:34 and SEQ ID. NO:35, in combination with a
pharmaceutically acceptable vehicle.
[0018] These and other aspects of the invention will become evident
upon reference to the following detailed description.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0019] The teachings of all the references cited herein are
incorporated in their entirety by reference.
[0020] Prior to setting forth the invention in detail, it may be
helpful to the understanding thereof to define the following
terms:
[0021] The term "affinity tag" is used herein to denote a
polypeptide segment that can be attached to a second polypeptide to
provide for purification or detection of the second polypeptide or
provide sites for attachment of the second polypeptide to a
substrate. In principal, any peptide or protein for which an
antibody or other specific binding agent is available can be used
as an affinity tag. Affinity tags include a poly-histidine tract,
protein A, Nilsson et al., EMBO J. 4:1075 (1985); Nilsson et al.,
Methods Enzymol. 198:3 (1991), glutathione S transferase, Smith and
Johnson, Gene 67:31 (1988), Glu-Glu affinity tag, Grussenmeyer et
al., Proc. Natl. Acad. Sci. USA 82:7952-4 (1985), substance P,
Flag.TM. peptide, Hopp et al., Biotechnology 6:1204-1210 (1988),
streptavidin binding peptide, or other antigenic epitope or binding
domain. See, in general, Ford et al., Protein Expression and
Purification 2: 95-107 (1991). DNAs encoding affinity tags are
available from commercial suppliers (e.g., Pharmacia Biotech,
Piscataway, N.J.).
[0022] The term "allelic variant" is used herein to denote any of
two or more alternative forms of a gene occupying the same
chromosomal locus. Allelic variation arises naturally through
mutation, and may result in phenotypic polymorphism within
populations. Gene mutations can be silent (no change in the encoded
polypeptide) or may encode polypeptides having altered amino acid
sequence. The term allelic variant is also used herein to denote a
protein encoded by an allelic variant of a gene.
[0023] The terms "amino-terminal" and "carboxyl-terminal" are used
herein to denote positions within polypeptides. Where the context
allows, these terms are used with reference to a particular
sequence or portion of a polypeptide to denote proximity or
relative position. For example, a certain sequence positioned
carboxyl-terminal to a reference sequence within a polypeptide is
located proximal to the carboxyl terminus of the reference
sequence, but is not necessarily at the carboxyl terminus of the
complete polypeptide.
[0024] The term "complement/anti-complement pair" denotes
non-identical moieties that form a non-covalently associated,
stable pair under appropriate conditions. For instance, biotin and
avidin (or streptavidin) are prototypical members of a
complement/anti-complement pair. Other exemplary
complement/anti-complement pairs include receptor/ligand pairs,
antibody/antigen (or hapten or epitope) pairs, sense/antisense
polynucleotide pairs, and the like. Where subsequent dissociation
of the complement/anti-complement pair is desirable, the
complement/anti-complement pair preferably has a binding affinity
of <10.sup.9 M.sup.-1.
[0025] The term "complements of a polynucleotide molecule" is a
polynucleotide molecule having a complementary base sequence and
reverse orientation as compared to a reference sequence. For
example, the sequence 5' ATGCACGGG 3' is complementary to 5'
CCCGTGCAT 3'.
[0026] The term "contig" denotes a polynucleotide that has a
contiguous stretch of identical or complementary sequence to
another polynucleotide. Contiguous sequences are said to "overlap"
a given stretch of polynucleotide sequence either in their entirety
or along a partial stretch of the polynucleotide. For example,
representative contigs to the polynucleotide sequence
5'-ATGGCTTAGCTT-3' are 5'-TAGCTTgagtct-3' and
3'-gtcgacTACCGA-5'.
[0027] The term "degenerate nucleotide sequence" denotes a sequence
of nucleotides that includes one or more degenerate codons (as
compared to a reference polynucleotide molecule that encodes a
polypeptide). Degenerate codons contain different triplets of
nucleotides, but encode the same amino acid residue (i.e., GAU and
GAC triplets each encode Asp).
[0028] The term "expression vector" is used to denote a DNA
molecule, linear or circular, that comprises a segment encoding a
polypeptide of interest operably linked to additional segments that
provide for its transcription. Such additional segments include
promoter and terminator sequences, and may also include one or more
origins of replication, one or more selectable markers, an
enhancer, a polyadenylation signal, etc. Expression vectors are
generally derived from plasmid or viral DNA, or may contain
elements of both.
[0029] The term "isolated", when applied to a polynucleotide,
denotes that the polynucleotide has been removed from its natural
genetic milieu and is thus free of other extraneous or unwanted
coding sequences, and is in a form suitable for use within
genetically engineered protein production systems. Such isolated
molecules are those that are separated from their natural
environment and include cDNA and genomic clones. Isolated DNA
molecules of the present invention are free of other genes with
which they are ordinarily associated, but may include naturally
occurring 5' and 3' untranslated regions such as promoters and
terminators. The identification of associated regions will be
evident to one of ordinary skill in the art (see for example, Dynan
and Tijan, Nature 316:774-78 (1985).
[0030] An "isolated" polypeptide or protein is a polypeptide or
protein that is found in a condition other than its native
environment, such as apart from blood and animal tissue. In a
preferred form, the isolated polypeptide is substantially free of
other polypeptides, particularly other polypeptides of animal
origin. It is preferred to provide the polypeptides in a highly
purified form, i.e. greater than 95% pure, more preferably greater
than 99% pure. When used in this context, the term "isolated" does
not exclude the presence of the same polypeptide in alternative
physical forms, such as dimers or alternatively glycosylated or
derivatized forms.
[0031] The term "operably linked", when referring to DNA segments,
indicates that the segments are arranged so that they function in
concert for their intended purposes, e.g., transcription initiates
in the promoter and proceeds through the coding segment to the
terminator.
[0032] The term "ortholog" denotes a polypeptide or protein
obtained from one species that is the functional counterpart of a
polypeptide or protein from a different species. Sequence
differences among orthologs are the result of speciation.
[0033] "Paralogs" are distinct but structurally related proteins
made by an organism. Paralogs are believed to arise through gene
duplication. For example, .alpha.-globin, .beta.-globin, and
myoglobin are paralogs of each other.
[0034] A "polynucleotide" is a single- or double-stranded polymer
of deoxyribonucleotide or ribonucleotide bases read from the 5' to
the 3' end. Polynucleotides include RNA and DNA, and may be
isolated from natural sources, synthesized in vitro, or prepared
from a combination of natural and synthetic molecules. Sizes of
polynucleotides are expressed as base pairs (abbreviated "bp"),
nucleotides ("nt"), or kilobases ("kb"). Where the context allows,
the latter two terms may describe polynucleotides that are
single-stranded or double-stranded. When the term is applied to
double-stranded molecules it is used to denote overall length and
will be understood to be equivalent to the term "base pairs". It
will be recognized by those skilled in the art that the two strands
of a double-stranded polynucleotide may differ slightly in length
and that the ends thereof may be staggered as a result of enzymatic
cleavage; thus all nucleotides within a double-stranded
polynucleotide molecule may not be paired. Such unpaired ends will
in general not exceed 20 nt in length.
[0035] A "polypeptide" is a polymer of amino acid residues joined
by peptide bonds, whether produced naturally or synthetically.
Polypeptides of less than about 10 amino acid residues are commonly
referred to as "peptides".
[0036] The term "promoter" is used herein for its art-recognized
meaning to denote a portion of a gene containing DNA sequences that
provide for the binding of RNA polymerase and initiation of
transcription. Promoter sequences are commonly, but not always,
found in the 5' non-coding regions of genes.
[0037] A "protein" is a macromolecule comprising one or more
polypeptide chains. A protein may also comprise non-peptidic
components, such as carbohydrate groups. Carbohydrates and other
non-peptidic substituents may be added to a protein by the cell in
which the protein is produced, and will vary with the type of cell.
Proteins are defined herein in terms of their amino acid backbone
structures; substituents such as carbohydrate groups are generally
not specified, but may be present nonetheless.
[0038] The term "receptor" denotes a cell-associated protein that
binds to a bioactive molecule (i.e., a ligand) and mediates the
effect of the ligand on the cell. Membrane-bound receptors are
characterized by a multi-domain structure comprising an
extracellular ligand-binding domain and an intracellular effector
domain that is typically involved in signal transduction. Binding
of ligand to receptor results in a conformational change in the
receptor that causes an interaction between the effector domain and
other molecule(s) in the cell. This interaction in turn leads to an
alteration in the metabolism of the cell. Metabolic events that are
linked to receptor-ligand interactions include gene transcription,
phosphorylation, dephosphorylation, increases in cyclic AMP
production, mobilization of cellular calcium, mobilization of
membrane lipids, cell adhesion, hydrolysis of inositol lipids and
hydrolysis of phospholipids. In general, receptors can be membrane
bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating
hormone receptor, beta-adrenergic receptor) or multimeric (e.g.,
PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF
receptor, G-CSF receptor, erythropoietin receptor and IL-6
receptor).
[0039] The term "secretory signal sequence" denotes a DNA sequence
that encodes a polypeptide (a "secretory peptide") that, as a
component of a larger polypeptide, directs the larger polypeptide
through a secretory pathway of a cell in which it is synthesized.
The larger polypeptide is commonly cleaved to remove the secretory
peptide during transit through the secretory pathway.
[0040] The term "splice variant" is used herein to denote
alternative forms of RNA transcribed from a gene. Splice variation
arises naturally through use of alternative splicing sites within a
transcribed RNA molecule, or less commonly between separately
transcribed RNA molecules, and may result in several mRNAs
transcribed from the same gene. Splice variants may encode
polypeptides having altered amino acid sequence. The term splice
variant is also used herein to denote a protein encoded by a splice
variant of an mRNA transcribed from a gene.
[0041] Molecular weights and lengths of polymers determined by
imprecise analytical methods (e.g., gel electrophoresis) will be
understood to be approximate values. When such a value is expressed
as "about" X or "approximately" X, the stated value of X will be
understood to be accurate to .+-.10%.
[0042] It is believed that Zcyto10 is of a member of the IL-10
subfamily of cytokines. Other members of this group include MDA-7,
IL-19, KFF. The conserved amino acids in the helix D of Zcyto10 can
be used as a tool to identify new family members. Helix D has is
the most highly conserved having about 32% identity with the helix
D of IL-10. For instance, reverse transcription-polymerase chain
reaction (RT-PCR) can be used to amplify sequences encoding the
conserved [the domain, region or motif from above] from RNA
obtained from a variety of tissue sources or cell lines. In
particular, highly degenerate primers designed from the Zcyto10
sequences are useful for this purpose.
[0043] Within certain embodiments of the invention the isolated
polynucleotides will hybridize to similar sized regions of SEQ ID
NO:1, SEQ ID NO:3, SEQ ID NO:18, SEQ ID NO:33 or a sequence
complementary thereto, under stringent conditions. In general,
stringent conditions are selected to be about 5.degree. C. lower
than the thermal melting point (T.sub.m) for the specific sequence
at a defined ionic strength and pH. The T.sub.m is the temperature
(under defined ionic strength and pH) at which 50% of the target
sequence hybridizes to a perfectly matched probe. Typical stringent
conditions are those in which the salt concentration is about 0.02
M or less at pH 7 and the temperature is at least about 60.degree.
C. As previously noted, the isolated polynucleotides of the present
invention include DNA and RNA. Methods for isolating DNA and RNA
are well known in the art. Total RNA can be prepared using
guanidine HCl extraction followed by isolation by centrifugation in
a CsCl gradient [Chirgwin et al., Biochemistry 18:52-94, (1979)].
Poly (A).sup.+ RNA is prepared from total RNA using the method of
Aviv and Leder, Proc. Natl. Acad. Sci. USA 69:1408-1412 (1972).
Complementary DNA (cDNA) is prepared from poly(A).sup.+ RNA using
known methods. Polynucleotides encoding Zcyto10 polypeptides are
then identified and isolated by, for example, hybridization or
PCR.
[0044] Additionally, the polynucleotides of the present invention
can be synthesized using a DNA synthesizer. Currently the method of
choice is the phosphoramidite method. If chemically synthesized
double stranded DNA is required for an application such as the
synthesis of a gene or a gene fragment, then each complementary
strand is made separately. The production of short genes (60 to 80
bp) is technically straightforward and can be accomplished by
synthesizing the complementary strands and then annealing them. For
the production of longer genes (>300 bp), however, special
strategies must be invoked, because the coupling efficiency of each
cycle during chemical DNA synthesis is seldom 100%. To overcome
this problem, synthetic genes (double-stranded) are assembled in
modular form from single-stranded fragments that are from 20 to 100
nucleotides in length. See Glick, Bernard R. and Jack J. Pasternak,
Molecular Biotechnology, Principles & Applications of
Recombinant DNA, (ASM Press, Washington, D.C. 1994), Itakura, K. et
al. Synthesis and use of synthetic oligonucleotides. Annu. Rev.
Biochem. 53: 323-356 (1984), and Climie, S. et al. Chemical
synthesis of the thymidylate synthase gene. Proc. Natl. Acad. Sci.
USA 87: 633-637 (1990).
[0045] Those skilled in the art will recognize that the sequences
disclosed in SEQ ID NOs:1, 2, 3 and 4 represent a two alleles of
the human, and SEQ ID NOs:18, 19, 33 and 34 represent two alleles
of the mouse. Additional allelic variants of these sequences can be
cloned by probing cDNA or genomic libraries from different
individuals according to standard procedures. Allelic variants of
this sequence can be cloned by probing cDNA or genomic libraries
from different individuals according to standard procedures.
Allelic variants of the DNA sequence shown in SEQ ID NO:1,
including those containing silent mutations and those in which
mutations result in amino acid sequence changes, are within the
scope of the present invention, as are proteins which are allelic
variants of SEQ ID NO:2. cDNAs generated from alternatively spliced
mRNAs, which retain the properties of the Zcyto10 polypeptide are
included within the scope of the present invention, as are
polypeptides encoded by such cDNAs and mRNAs. Allelic variants and
splice variants of these sequences can be cloned by probing cDNA or
genomic libraries from different individuals or tissues according
to standard procedures known in the art.
[0046] The present invention further provides counterpart proteins
and polynucleotides from other species ("species orthologs"). Of
particular interest are Zcyto10 polypeptides from other mammalian
species, including murine, porcine, ovine, bovine, canine, feline,
equine, and other primates. Species orthologs of the human Zcyto10
protein can be cloned using information and compositions provided
by the present invention in combination with conventional cloning
techniques. For example, a cDNA can be cloned using mRNA obtained
from a tissue or cell type that expresses the protein. Suitable
sources of mRNA can be identified by probing Northern blots with
probes designed from the sequences disclosed herein. A library is
then prepared from mRNA of a positive tissue or cell line. A
protein-encoding cDNA can then be isolated by a variety of methods,
such as by probing with a complete or partial human or mouse cDNA
or with one or more sets of degenerate probes based on the
disclosed sequences. A cDNA can also be cloned using the polymerase
chain reaction, or PCR (Mullis et al. U.S. Pat. No. 4,683,202),
using primers designed from the sequences disclosed herein. Within
an additional method, the cDNA library can be used to transform or
transfect host cells and expression of the cDNA of interest can be
detected with an antibody to the protein. Similar techniques can
also be applied to the isolation of genomic clones. As used and
claimed, the language "an isolated polynucleotide which encodes a
polypeptide, said polynucleotide being defined by SEQ ID NOs: 2, 4
12, 13, 19, 20, 25, 26, 34 and 35" includes all allelic variants
and species orthologs of these polypeptides.
[0047] The present invention also provides isolated protein
polypeptides that are substantially identical to the protein
polypeptides of SEQ ID NO: 2 and its species orthologs. By
"isolated" is meant a protein or polypeptide that is found in a
condition other than its native environment, such as apart from
blood and animal tissue. In a preferred form, the isolated
polypeptide is substantially free of other polypeptides,
particularly other polypeptides of animal origin. It is preferred
to provide the polypeptides in a highly purified form, i.e. greater
than 95% pure, more preferably greater than 99% pure. The term
"substantially identical" is used herein to denote polypeptides
having 50%, preferably 60%, more preferably at least 80%, sequence
identity to the sequence shown in SEQ ID NOs: 2, 4 12, 13, 19, 20,
25, 26, 34 and 35, or their species orthologs. Such polypeptides
will more preferably be at least 90% identical, and most preferably
95% or more identical to SEQ ID NO:2, or its species orthologs.
Percent sequence identity is determined by conventional methods.
See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616
(1986) and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA
89:10915-10919 (1992). Briefly, two amino acid sequences are
aligned to optimize the alignment scores using a gap opening
penalty of 10, a gap extension penalty of 1, and the "blossom 62"
scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 1
(amino acids are indicated by the standard one-letter codes). The
percent identity is then calculated as:
Total number of identical matches [ length of the longer sequence
plus the number of gaps introduced into the longer sequence in
order to align the two sequences ] .times. 100 ##EQU00001##
TABLE-US-00001 TABLE 1 A R N D C Q E G H I L K M F P S T W Y V A 4
R -1 5 N -2 0 6 D -2 -2 1 6 C 0 -3 -3 -3 9 Q -1 1 0 0 -3 5 E -1 0 0
2 -4 2 5 G 0 -2 0 -1 -3 -2 -2 6 H -2 0 1 -1 -3 0 0 -2 8 I -1 -3 -3
-3 -1 -3 -3 -4 -3 4 L -1 -2 -3 -4 -1 -2 -3 -4 -3 2 4 K -1 2 0 -1 -3
1 1 -2 -1 -3 -2 5 M -1 -1 -2 -3 -1 0 -2 -3 -2 1 2 -1 5 F -2 -3 -3
-3 -2 -3 -3 -3 -1 0 0 -3 0 6 P -1 -2 -2 -1 -3 -1 -1 -2 -2 -3 -3 -1
-2 -4 7 S 1 -1 1 0 -1 0 0 0 -1 -2 -2 0 -1 -2 -1 4 T 0 -1 0 -1 -1 -1
-1 -2 -2 -1 -1 -1 -1 -2 -1 1 5 W -3 -3 -4 -4 -2 -2 -3 -2 -2 -3 -2
-3 -1 1 -4 -3 -2 11 Y -2 -2 -2 -3 -2 -1 -2 -3 2 -1 -1 -2 -1 3 -3 -2
-2 2 7 V 0 -3 -3 -3 -1 -2 -2 -3 -3 3 1 -2 1 -1 -2 -2 0 -3 -1 4
[0048] Sequence identity of polynucleotide molecules is determined
by similar methods using a ratio as disclosed above.
[0049] Variant Zcyto10 polypeptides or substantially identical
proteins and polypeptides are characterized as having one or more
amino acid substitutions, deletions or additions. These changes are
preferably of a minor nature, that is conservative amino acid
substitutions (see Table 2) and other substitutions that do not
significantly affect the folding or activity of the protein or
polypeptide; small deletions, typically of one to about 30 amino
acids; and small amino- or carboxyl-terminal extensions, such as an
amino-terminal methionine residue, a small linker peptide of up to
about 20-25 residues, or a small extension that facilitates
purification (an affinity tag), such as a poly-histidine tract,
protein A, Nilsson et al., EMBO J. 4:1075 (1985); Nilsson et al.,
Methods Enzymol. 198:3 (1991), glutathione S transferase, Smith and
Johnson, Gene 67:31 (1988), or other antigenic epitope or binding
domain. See, in general Ford et al., Protein Expression and
Purification 2: 95-107 (1991). DNAs encoding affinity tags are
available from commercial suppliers (e.g., Pharmacia Biotech,
Piscataway, N.J.).
TABLE-US-00002 TABLE 2 Conservative amino acid substitutions Basic:
arginine lysine histidine Acidic: glutamic acid aspartic acid
Polar: glutamine asparagine Hydrophobic: leucine isoleucine valine
Aromatic: phenylalanine tryptophan tyrosine Small: glycine alanine
serine threonine methionine
[0050] The present invention further provides a variety of other
polypeptide fusions [and related multimeric proteins comprising one
or more polypeptide fusions]. For example, a Zcytol0 polypeptide
can be prepared as a fusion to a dimerizing protein as disclosed in
U.S. Pat. Nos. 5,155,027 and 5,567,584. Preferred dimerizing
proteins in this regard include immunoglobulin constant region
domains Immunoglobulin-Zcyto10 polypeptide fusions can be expressed
in genetically engineered cells [to produce a variety of multimeric
Zcyto10 analogs]. Auxiliary domains can be fused to Zcyto10
polypeptides to target them to specific cells, tissues, or
macromolecules (e.g., collagen). For example, a Zcyto10 polypeptide
or protein could be targeted to a predetermined cell type by fusing
a polypeptide to a ligand that specifically binds to a receptor on
the surface of the target cell. In this way, polypeptides and
proteins can be targeted for therapeutic or diagnostic purposes. A
Zcyto10 polypeptide can be fused to two or more moieties, such as
an affinity tag for purification and a targeting domain.
Polypeptide fusions can also comprise one or more cleavage sites,
particularly between domains. See, Tuan et al., Connective Tissue
Research 34:1-9 (1996).
[0051] The proteins of the present invention can also comprise
non-naturally occurring amino acid residues. Non-naturally
occurring amino acids include, without limitation,
trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline,
trans-4-hydroxyproline, N-methylglycine, allo-threonine,
methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine,
nitroglutamine, homoglutamine, pipecolic acid, thiazolidine
carboxylic acid, dehydroproline, 3- and 4-methylproline,
3,3-dimethylproline, tert-leucine, norvaline, 2-azaphenylalanine,
3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine.
Several methods are known in the art for incorporating
non-naturally occurring amino acid residues into proteins. For
example, an in vitro system can be employed wherein nonsense
mutations are suppressed using chemically aminoacylated suppressor
tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA
are known in the art. Essential amino acids in the polypeptides of
the present invention can be identified according to procedures
known in the art, such as site-directed mutagenesis or
alanine-scanning mutagenesis [Cunningham and Wells, Science 244:
1081-1085 (1989)]; Bass et al., Proc. Natl. Acad. Sci. USA
88:4498-4502 (1991). In the latter technique, single alanine
mutations are introduced at every residue in the molecule, and the
resultant mutant molecules are tested for biological activity
(e.g., ligand binding and signal transduction) to identify amino
acid residues that are critical to the activity of the molecule.
Sites of ligand-protein interaction can also be determined by
analysis of crystal structure as determined by such techniques as
nuclear magnetic resonance, crystallography or photoaffinity
labeling. See, for example, de Vos et al., Science 255:306-312
(1992); Smith et al., J. Mol. Biol. 224:899-904 (1992); Wlodaver et
al., FEBS Lett. 309:59-64 (1992). The identities of essential amino
acids can also be inferred from analysis of homologies with related
proteins.
[0052] Multiple amino acid substitutions can be made and tested
using known methods of mutagenesis and screening, such as those
disclosed by Reidhaar-Olson and Sauer, Science 241:53-57 (1988) or
Bowie and Sauer Proc. Natl. Acad. Sci. USA 86:2152-2156 (1989).
Briefly, these authors disclose methods for simultaneously
randomizing two or more positions in a polypeptide, selecting for
functional polypeptide, and then sequencing the mutagenized
polypeptides to determine the spectrum of allowable substitutions
at each position. Other methods that can be used include phage
display (e.g., Lowman et al., Biochem. 30:10832-10837 (1991);
Ladner et al., U.S. Pat. No. 5,223,409; Huse, WIPO Publication WO
92/06204) and region-directed mutagenesis, Derbyshire et al., Gene
46:145 (1986); Ner et al., DNA 7:127 (1988).
[0053] Mutagenesis methods as disclosed above can be combined with
high-throughput screening methods to detect activity of cloned,
mutagenized proteins in host cells. Preferred assays in this regard
include cell proliferation assays and biosensor-based
ligand-binding assays, which are described below. Mutagenized DNA
molecules that encode active proteins or portions thereof (e.g.,
ligand-binding fragments) can be recovered from the host cells and
rapidly sequenced using modern equipment. These methods allow the
rapid determination of the importance of individual amino acid
residues in a polypeptide of interest, and can be applied to
polypeptides of unknown structure.
[0054] Using the methods discussed above, one of ordinary skill in
the art can prepare a variety of polypeptides that are
substantially identical to SEQ ID NOs: 2, 4 12, 13, 19, 20, 25, 26,
34 and 35 or allelic variants thereof and retain the properties of
the wild-type protein. As expressed and claimed herein the
language, "a polypeptide as defined by SEQ ID NO: 2" includes all
allelic variants and species orthologs of the polypeptide.
[0055] The protein polypeptides of the present invention, including
full-length proteins, protein fragments (e.g. ligand-binding
fragments), and fusion polypeptides can be produced in genetically
engineered host cells according to conventional techniques.
Suitable host cells are those cell types that can be transformed or
transfected with exogenous DNA and grown in culture, and include
bacteria, fungal cells, and cultured higher eukaryotic cells.
Eukaryotic cells, particularly cultured cells of multicellular
organisms, are preferred. Techniques for manipulating cloned DNA
molecules and introducing exogenous DNA into a variety of host
cells are disclosed by Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y., 1989), and Ausubel et al., ibid.
[0056] Polynucleotides, generally a cDNA sequence, of the present
invention encode the above-described polypeptides. A DNA sequence
which encodes a polypeptide of the present invention is comprised
of a series of codons, each amino acid residue of the polypeptide
being encoded by a codon and each codon being comprised of three
nucleotides. The amino acid residues are encoded by their
respective codons as follows.
[0057] Alanine (Ala) is encoded by GCA, GCC, GCG or GCT;
[0058] Cysteine (Cys) is encoded by TGC or TGT;
[0059] Aspartic acid (Asp) is encoded by GAC or GAT;
[0060] Glutamic acid (Glu) is encoded by GAA or GAG;
[0061] Phenylalanine (Phe) is encoded by TTC or TTT;
[0062] Glycine (Gly) is encoded by GGA, GGC, GGG or GGT;
[0063] Histidine (His) is encoded by CAC or CAT;
[0064] Isoleucine (Ile) is encoded by ATA, ATC or ATT;
[0065] Lysine (Lys) is encoded by AAA, or AAG;
[0066] Leucine (Leu) is encoded by TTA, TTG, CTA, CTC, CTG or
CTT;
[0067] Methionine (Met) is encoded by ATG;
[0068] Asparagine (Asn) is encoded by AAC or AAT;
[0069] Proline (Pro) is encoded by CCA, CCC, CCG or CCT;
[0070] Glutamine (Gln) is encoded by CAA or CAG;
[0071] Arginine (Arg) is encoded by AGA, AGG, CGA, CGC, CGG or
CGT;
[0072] Serine (Ser) is encoded by AGC, AGT, TCA, TCC, TCG or
TCT;
[0073] Threonine (Thr) is encoded by ACA, ACC, ACG or ACT;
[0074] Valine (Val) is encoded by GTA, GTC, GTG or GTT;
[0075] Tryptophan (Trp) is encoded by TGG; and
[0076] Tyrosine (Tyr) is encoded by TAC or TAT.
[0077] It is to be recognized that according to the present
invention, when a cDNA is claimed as described above, it is
understood that what is claimed are both the sense strand, the
anti-sense strand, and the DNA as double-stranded having both the
sense and anti-sense strand annealed together by their respective
hydrogen bonds. Also claimed is the messenger RNA (mRNA) which
encodes the polypeptides of the present invention, and which mRNA
is encoded by the above-described cDNA. A messenger RNA (mRNA) will
encode a polypeptide using the same codons as those defined above,
with the exception that each thymine nucleotide (T) is replaced by
a uracil nucleotide (U).
[0078] In general, a DNA sequence encoding a Zcyto10 polypeptide is
operably linked to other genetic elements required for its
expression, generally including a transcription promoter and
terminator, within an expression vector. The vector will also
commonly contain one or more selectable markers and one or more
origins of replication, although those skilled in the art will
recognize that within certain systems selectable markers may be
provided on separate vectors, and replication of the exogenous DNA
may be provided by integration into the host cell genome. Selection
of promoters, terminators, selectable markers, vectors and other
elements is a matter of routine design within the level of ordinary
skill in the art. Many such elements are described in the
literature and are available through commercial suppliers.
[0079] To direct a Zcyto10 polypeptide into the secretory pathway
of a host cell, a secretory signal sequence (also known as a leader
sequence, prepro sequence or pre sequence) is provided in the
expression vector. The secretory signal sequence may be that of the
protein, or may be derived from another secreted protein (e.g.,
t-PA) or synthesized de novo. The secretory signal sequence is
joined to the Zcyto10 DNA sequence in the correct reading frame.
Secretory signal sequences are commonly positioned 5' to the DNA
sequence encoding the polypeptide of interest, although certain
signal sequences may be positioned elsewhere in the DNA sequence of
interest (see, e.g., Welch et al., U.S. Pat. No. 5,037,743; Holland
et al., U.S. Pat. No. 5,143,830).
[0080] Methods for introducing exogenous DNA into mammalian host
cells include calcium phosphate-mediated transfection, Wigler et
al., Cell 14:725 (1978); Corsaro and Pearson, Somatic Cell Genetics
7:603, 1981: Graham and Van der Eb, Virology 52:456 (1973),
electroporation, Neumann et al., EMBO J. 1:841-845 (1982),
DEAE-dextran mediated transfection, Ausubel et al., eds., Current
Protocols in Molecular Biology, (John Wiley and Sons, Inc., NY,
1987), and liposome-mediated transfection, Hawley-Nelson et al.,
Focus 15:73 (1993); Ciccarone et al., Focus 15:80 (1993). The
production of recombinant polypeptides in cultured mammalian cells
is disclosed, for example, by Levinson et al., U.S. Pat. No.
4,713,339; Hagen et al., U.S. Pat. No. 4,784,950; Palmiter et al.,
U.S. Pat. No. 4,579,821; and Ringold, U.S. Pat. No. 4,656,134.
Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL
1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570
(ATCC No. CRL 10314), 293 [ATCC No. CRL 1573; Graham et al., J.
Gen. Virol. 36:59-72 (1977) and Chinese hamster ovary (e.g. CHO-K1;
ATCC No. CCL 61) cell lines. Additional suitable cell lines are
known in the art and available from public depositories such as the
American Type Culture Collection, Rockville, Md. In general, strong
transcription promoters are preferred, such as promoters from SV-40
or cytomegalovirus. See, e.g., U.S. Pat. No. 4,956,288. Other
suitable promoters include those from metallothionein genes (U.S.
Pat. Nos. 4,579,821 and 4,601,978 and the adenovirus major late
promoter.
[0081] Drug selection is generally used to select for cultured
mammalian cells into which foreign DNA has been inserted. Such
cells are commonly referred to as "transfectants". Cells that have
been cultured in the presence of the selective agent and are able
to pass the gene of interest to their progeny are referred to as
"stable transfectants." A preferred selectable marker is a gene
encoding resistance to the antibiotic neomycin. Selection is
carried out in the presence of a neomycin-type drug, such as G-418
or the like. Selection systems may also be used to increase the
expression level of the gene of interest, a process referred to as
"amplification." Amplification is carried out by culturing
transfectants in the presence of a low level of the selective agent
and then increasing the amount of selective agent to select for
cells that produce high levels of the products of the introduced
genes. A preferred amplifiable selectable marker is dihydrofolate
reductase, which confers resistance to methotrexate. Other drug
resistance genes (e.g. hygromycin resistance, multi-drug
resistance, puromycin acetyltransferase) can also be used.
Alternative markers that introduce an altered phenotype, such as
green fluorescent protein, or cell surface proteins such as CD4,
CD8, Class I MHC, placental alkaline phosphatase may be used to
sort transfected cells from untransfected cells by such means as
FACS sorting or magnetic bead separation technology.
[0082] Other higher eukaryotic cells can also be used as hosts,
including insect cells, plant cells and avian cells. Transformation
of insect cells and production of foreign polypeptides therein is
disclosed by Guarino et al., U.S. Pat. No. 5,162,222; Bang et al.,
U.S. Pat. No. 4,775,624; and WIPO publication WO 94/06463. The use
of Agrobacterium rhizogenes as a vector for expressing genes in
plant cells has been reviewed by Sinkar et al., J. Biosci.
(Bangalore) 11:47-58 (1987). Insect cells can be infected with
recombinant baculovirus, commonly derived from Autographa
californica nuclear polyhedrosis virus (AcNPV). See, King, L. A.
and Possee, R. D., The Baculovirus Expression System: A Laboratory
Guide (Chapman & Hall, London); O'Reilly, D. R. et al.,
Baculovirus Expression Vectors: A Laboratory Manual (University
Press., New York, Oxford, 1994); and, Richardson, C. D., Ed.,
Baculovirus Expression Protocols. Methods in Molecular Biology,
(Humana Press, Totowa, N.J., 1995). A second method of making
recombinant Zcyto10 baculovirus utilizes a transposon-based system
described by Luckow, V. A, et al., J Virol 67:4566-79 1993). This
system, which utilizes transfer vectors, is sold in the
Bac-to-Bac.TM. kit (Life Technologies, Rockville, Md.). This system
utilizes a transfer vector, pFastBacl.TM. (Life Technologies)
containing a Tn7 transposon to move the DNA encoding the Zcyto10
polypeptide into a baculovirus genome maintained in E. coli as a
large plasmid called a "bacmid." See, Hill-Perkins, M. S. and
Possee, R. D., J Gen Virol 71:971-6, (1990); Bonning, B. C. et al.,
J Gen Virol 75:1551-6 (1994); and, Chazenbalk, G. D., and Rapoport,
B., J Biol Chem 270:1543-9 (1995). In addition, transfer vectors
can include an in-frame fusion with DNA encoding an epitope tag at
the C- or N-terminus of the expressed Zcyto10 polypeptide, for
example, a Glu-Glu epitope tag, Grussenmeyer, T. et al., Proc.
Natl. Acad. Sci. 82:7952-4 (1985). Using a technique known in the
art, a transfer vector containing Zcyto10 is transformed into E.
Coli, and screened for bacmids which contain an interrupted lacZ
gene indicative of recombinant baculovirus. The bacmid DNA
containing the recombinant baculovirus genome is isolated, using
common techniques, and used to transfect Spodoptera frugiperda
cells, e.g. Sf9 cells. Recombinant virus that expresses Zcyto10 is
subsequently produced. Recombinant viral stocks are made by methods
commonly used the art.
[0083] The recombinant virus is used to infect host cells,
typically a cell line derived from the fall armyworm, Spodoptera
frugiperda. See, in general, Glick and Pasternak, Molecular
Biotechnology Principles and Applications of Recombinant DNA, ASM
Press, Washington, D.C. (1994). Another suitable cell line is the
High FiveO.TM. cell line (Invitrogen) derived from Trichoplusia ni
(U.S. Pat. No. 5,300,435). Commercially available serum-free media
are used to grow and maintain the cells. Suitable media are Sf900
II.TM. (Life Technologies) or ESF 921.TM. (Expression Systems) for
the Sf9 cells; and Ex-cellO405.TM. (JRH Biosciences, Lenexa, Kans.)
or Express FiveO.TM. (Life Technologies) for the T. ni cells. The
cells are grown up from an inoculation density of approximately
2-5.times.105 cells to a density of 1-2.times.106 cells at which
time a recombinant viral stock is added at a multiplicity of
infection (MOI) of 0.1 to 10, more typically near 3. Procedures
used are generally described in available laboratory manuals (King,
L. A. and Possee, R. D., ibid.; O'Reilly, D. R. et al., ibid.;
Richardson, C. D., ibid.). Subsequent purification of the Zcyto10
polypeptide from the supernatant can be achieved using methods
described herein.
[0084] Fungal cells, including yeast cells, and particularly cells
of the genus Saccharomyces, can also be used within the present
invention, such as for producing protein fragments or polypeptide
fusions. Methods for transforming yeast cells with exogenous DNA
and producing recombinant polypeptides therefrom are disclosed by,
for example, Kawasaki, U.S. Pat. No. 4,599,311; Kawasaki et al.,
U.S. Pat. No. 4,931,373; Brake, U.S. Pat. No. 4,870,008; Welch et
al., U.S. Pat. No. 5,037,743; and Murray et al., U.S. Pat. No.
4,845,075. Transformed cells are selected by phenotype determined
by the selectable marker, commonly drug resistance or the ability
to grow in the absence of a particular nutrient (e.g., leucine). A
preferred vector system for use in yeast is the POT1 vector system
disclosed by Kawasaki et al. (U.S. Pat. No. 4,931,373), which
allows transformed cells to be selected by growth in
glucose-containing media. Suitable promoters and terminators for
use in yeast include those from glycolytic enzyme genes (see, e.g.,
Kawasaki, U.S. Pat. No. 4,599,311; Kingsman et al., U.S. Pat. No.
4,615,974; and Bitter, U.S. Pat. No. 4,977,092 and alcohol
dehydrogenase genes. See also U.S. Pat. Nos. 4,990,446; 5,063,154;
5,139,936 and 4,661,454. Transformation systems for other yeasts,
including Hansenula polymorpha, Schizosaccharomyces pombe,
Kluyveromyces lactis, Kluyveromyces fragilis, Ustilago maydis,
Pichia pastoris, Pichia methanolica, Pichia guillermondii and
Candida maltosa are known in the art. See, for example, Gleeson et
al., J. Gen. Microbiol. 132:3459-3465 (1986) and Cregg, U.S. Pat.
No. 4,882,279. Aspergillus cells may be utilized according to the
methods of McKnight et al., U.S. Pat. No. 4,935,349. Methods for
transforming Acremonium chrysogenum are disclosed by Sumino et al.,
U.S. Pat. No. 5,162,228. Methods for transforming Neurospora are
disclosed by Lambowitz, U.S. Pat. No. 4,486,533.
[0085] The use of Pichia methanolica as host for the production of
recombinant proteins is disclosed in WIPO Publications WO 97/17450,
WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in
transforming P. methanolica will commonly be prepared as
double-stranded, circular plasmids, which are preferably linearized
prior to transformation. For polypeptide production in P.
methanolica, it is preferred that the promoter and terminator in
the plasmid be that of a P. methanolica gene, such as a P.
methanolica alcohol utilization gene (AUG1 or AUG2). Other useful
promoters include those of the dihydroxyacetone synthase (DHAS),
formate dehydrogenase (FMD), and catalase (CA7) genes. To
facilitate integration of the DNA into the host chromosome, it is
preferred to have the entire expression segment of the plasmid
flanked at both ends by host DNA sequences. A preferred selectable
marker for use in Pichia methanolica is a P. methanolica ADE2 gene,
which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC
4.1.1.21), which allows ade2 host cells to grow in the absence of
adenine. For large-scale, industrial processes where it is
desirable to minimize the use of methanol, it is preferred to use
host cells in which both methanol utilization genes (AUG1 and AUG2)
are deleted. For production of secreted proteins, host cells
deficient in vacuolar protease genes (PEP4 and PRB1) are preferred.
Electroporation is used to facilitate the introduction of a plasmid
containing DNA encoding a polypeptide of interest into P.
methanolica cells. It is preferred to transform P. methanolica
cells by electroporation using an exponentially decaying, pulsed
electric field having a field strength of from 2.5 to 4.5 kV/cm,
preferably about 3.75 kV/cm, and a time constant (t) of from 1 to
40 milliseconds, most preferably about 20 milliseconds.
[0086] Prokaryotic host cells, including strains of the bacteria
Escherichia coli, Bacillus and other genera are also useful host
cells within the present invention. Techniques for transforming
these hosts and expressing foreign DNA sequences cloned therein are
well known in the art (see, e.g., Sambrook et al., ibid.). When
expressing a Zcyto10 polypeptide in bacteria such as E. coli, the
polypeptide may be retained in the cytoplasm, typically as
insoluble granules, or may be directed to the periplasmic space by
a bacterial secretion sequence. In the former case, the cells are
lysed, and the granules are recovered and denatured using, for
example, guanidine isothiocyanate or urea. The denatured
polypeptide can then be refolded and dimerized by diluting the
denaturant, such as by dialysis against a solution of urea and a
combination of reduced and oxidized glutathione, followed by
dialysis against a buffered saline solution. In the latter case,
the polypeptide can be recovered from the periplasmic space in a
soluble and functional form by disrupting the cells (by, for
example, sonication or osmotic shock) to release the contents of
the periplasmic space and recovering the protein, thereby obviating
the need for denaturation and refolding.
[0087] Transformed or transfected host cells are cultured according
to conventional procedures in a culture medium containing nutrients
and other components required for the growth of the chosen host
cells. A variety of suitable media, including defined media and
complex media, are known in the art and generally include a carbon
source, a nitrogen source, essential amino acids, vitamins and
minerals. Media may also contain such components as growth factors
or serum, as required. The growth medium will generally select for
cells containing the exogenously added DNA by, for example, drug
selection or deficiency in an essential nutrient which is
complemented by the selectable marker carried on the expression
vector or co-transfected into the host cell. P. methanolica cells
are cultured in a medium comprising adequate sources of carbon,
nitrogen and trace nutrients at a temperature of about 25.degree.
C. to 35.degree. C. Liquid cultures are provided with sufficient
aeration by conventional means, such as shaking of small flasks or
sparging of fermentors. A preferred culture medium for P.
methanolica is YEPD (2% D-glucose, 2% Bacto.TM. Peptone (Difco
Laboratories, Detroit, Mich.), 1% Bacto.TM. yeast extract (Difco
Laboratories), 0.004% adenine and 0.006% L-leucine).
[0088] Within one aspect of the present invention, a novel protein
is produced by a cultured cell, and the cell is used to screen for
a receptor or receptors for the protein, including the natural
receptor, as well as agonists and antagonists of the natural
ligand.
Protein Isolation:
[0089] It is preferred to purify the polypeptides of the present
invention to .gtoreq.80% purity, more preferably to .gtoreq.90%
purity, even more preferably .gtoreq.95% purity, and particularly
preferred is a pharmaceutically pure state, that is greater than
99.9% pure with respect to contaminating macromolecules,
particularly other proteins and nucleic acids, and free of
infectious and pyrogenic agents. Preferably, a purified polypeptide
is substantially free of other polypeptides, particularly other
polypeptides of animal origin.
[0090] Expressed recombinant polypeptides (or chimeric
polypeptides) can be purified using fractionation and/or
conventional purification methods and media. Ammonium sulfate
precipitation and acid or chaotrope extraction may be used for
fractionation of samples. Exemplary purification steps may include
hydroxyapatite, size exclusion, FPLC and reverse-phase high
performance liquid chromatography. Suitable anion exchange media
include derivatized dextrans, agarose, cellulose, polyacrylamide,
specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives
are preferred, with DEAE Fast-Flow Sepharose (Pharmacia,
Piscataway, N.J.) being particularly preferred. Exemplary
chromatographic media include those media derivatized with phenyl,
butyl, or octyl groups, such as Phenyl-Sepharose.TM. FF
(Pharmacia), Toyopearl.TM. butyl 650 (Toso Haas, Montgomeryville,
Pa.), Octyl-Sepharose.TM. (Pharmacia) and the like; or polyacrylic
resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable
solid supports include glass beads, silica-based resins, cellulosic
resins, agarose beads, cross-linked agarose beads, polystyrene
beads, cross-linked polyacrylamide resins and the like that are
insoluble under the conditions in which they are to be used. These
supports may be modified with reactive groups that allow attachment
of proteins by amino groups, carboxyl groups, sulfhydryl groups,
hydroxyl groups and/or carbohydrate moieties. Examples of coupling
chemistries include cyanogen bromide activation,
N-hydroxysuccinimide activation, epoxide activation, sulfhydryl
activation, hydrazide activation, and carboxyl and amino
derivatives for carbodiimide coupling chemistries. These and other
solid media are well known and widely used in the art, and are
available from commercial suppliers. Methods for binding receptor
polypeptides to support media are well known in the art. Selection
of a particular method is a matter of routine design and is
determined in part by the properties of the chosen support. See,
for example, Affinity Chromatography: Principles & Methods
(Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988).
[0091] The polypeptides of the present invention can be isolated by
exploitation of their properties. For example, immobilized metal
ion adsorption (IMAC) chromatography can be used to purify
histidine-rich proteins. Briefly, a gel is first charged with
divalent metal ions to form a chelate (E. Sulkowski, Trends in
Biochem. 3:1-7 (1985). Histidine-rich proteins will be adsorbed to
this matrix with differing affinities, depending upon the metal ion
used, and will be eluted by competitive elution, lowering the pH,
or use of strong chelating agents. Other methods of purification
include purification of glycosylated proteins by lectin affinity
chromatography and ion exchange chromatography (Methods in
Enzymol., Vol. 182, "Guide to Protein Purification", M. Deutscher,
(ed.), pp. 529-539 (Acad. Press, San Diego, 1990)). Alternatively,
a fusion of the polypeptide of interest and an affinity tag (e.g.,
polyhistidine, maltose-binding protein, an immunoglobulin domain)
may be constructed to facilitate purification.
Uses
[0092] The polypeptide of the present invention has the structural
characteristics of a four-helix bundle cytokine. A protein is
generally characterized as a cytokine by virtue of its solubility
and ability to act via cell surface receptors to signal and
modulate cell proliferation. Cytokines fall into several tertiary
structural fold classes, including cysteine-rich dimers (e.g.,
insulin, PDGF), beta-trefoil folds (e.g., FGF, IL-1), and all-alpha
four helix bundles. The latter are characterized by four helices,
labeled A,B,C and D, in a unique up-up-down-down topology, where
two overhand loops link helices A and B and helices C and D. See,
for example, Manavalan et al., Journal of Protein Chemistry 11(3):
321-31, (1992). The four-helix bundle cytokines are sometimes
further subdivided into short chain (e.g., IL-4, 11-2, GM-CSF) and
long chain (e.g., TPO, growth hormone, leptin, IL-10), where the
latter generally display longer A and D helices and overhand loops.
Henceforth we shall use the term "cytokine" synonymously with
"four-helix bundle cytokine". Helix A of zcyto10 includes amino
acid residue 35, an isoleucine, through amino acid residue 49, an
isoleucine, also defined by SEQ ID NO:14; helix B includes amino
acid 91, a leucine, through amino acid 105, a threonine, also
defined by SEQ ID NO:15; helix C includes amino acid residue 112, a
leucine, through amino acid residue 126, a cysteine, also defined
by SEQ ID NO:16; helix D includes amino acid residue 158, a valine,
through amino acid residue 172, a methionine, also defined by SEQ
ID NO:17.
[0093] Human Zcyto10 has an intramolecular disulfide bond between
Cys33 and Cys126. The other four cysteines, Cys80, Cys132, Cys81
and Cys134 are predicted to form two intramolecular disulfide bonds
in the arrangement Cys80-Cys132 and Cys81-Cys134. Residues that are
predicted to be crucial for the structural stability of Zcyto10
include Cys33, Cys126, Cys80, Cys132, Cys81 and Cys134. Mutation of
any one of these residues to any other residue is expected to
inactivate the function of Zcyto 10.
[0094] The structural stability of Zcyto10 is also dependent on the
maintenance of a buried hydrophobic face on the four alpha helices.
Residues Ile42, Phe46, Ile49, Leu91, Val94, Phe95, Tyr98, Leu112,
Phe116, Ile119, Leu123, Val158, Leu162, Leu165, Leu168, Leu169 and
Met172 are predicted to be buried in the core of the protein and if
they are changed, the substituted amino acid residue must be a
hydrophobic amino acid.
[0095] Residues expected to be involved in binding of Zcyto10 to a
cell surface receptor include Asp57, on the overhand loop between
helix A and B, and Lys160 and Glu164, charged residues predicted to
be exposed on the surface of helix D. On the surface of the
protein, on the loop AB and helix D areas, is a hydrophobic surface
patch comprising residues Ile62, Leu71, Ile167, and Trp171. These
residues may interact with a hydrophobic surface patch on a cell
surface receptor.
[0096] The human Zcyto10 polypeptide of the present invention has
about a 28% identity to interleukin-10 (IL-10). Mouse Zcyto10
polypeptide has approximately 24% identity to human IL-10, and
about 27% identity to mouse IL-10. Human Zcyto10 polypeptide has
approximately 76% identity with mouse Zcyto10 polypeptide.
[0097] Helix A of mouse Zcyto10 includes amino acid residue 35, an
isoleucine, through amino acid residue 49, an arginine, of SEQ ID
NO: 19, also defined by SEQ ID NO:21. Helix B of mouse Zcyto10
includes amino acid residue 91, a leucine, through amino acid
residue 105, a threonine, of SEQ ID NO: 19, also defined by SEQ ID
NO: 22. Helix C of mouse Zcyto10 includes amino acid residue 112, a
leucine, through amino acid residue 126, a cysteine, of SEQ ID NO:
19, also defined by SEQ ID NO: 23. Helix D of mouse Zcyto10
includes amino acid residue 158, a valine, through amino acid
residue 172, a methionine, of SEQ ID NO: 19, also defined by SEQ ID
NO:24.
[0098] IL-10 is a cytokine that inhibits production of other
cytokines, induces proliferation and differentiation of activated B
lymphocytes, inhibits HIV-1 replication and exhibits antagonistic
effects on gamma interferon. IL-10 appears to exist as a dimer
formed from two alpha-helical polypeptide regions related by a
180.degree. rotation. See, for example, Zdanov et al., Structure:
3(6): 591-601 (1996). IL-10 has been reported to be a product of
activated Th2 T-cells, B-cells, keratinocytes and
monocytes/macrophages that is capable of modulating a Th1 T-cell
response. Such modulation may be accomplished by inhibiting
cytokine synthesis by Th1 T-cells. See, for example, Hus et al.,
Int. Immunol. 4:563 (1992) and D'Andrea et al., J. Exp. Med.
178:1042 (1992). IL-10 has also been reported to inhibit cytokine
synthesis by natural killer cells and monocytes/macrophages. See,
for example, Hus et al., cited above and Fiorentino et al., J.
Immunol. 146: 3444 (1991). In addition, IL-10 has been found to
have a protective effect with respect to insulin dependent diabetes
mellitus.
[0099] In analysis of the tissue distribution of the mRNA
corresponding to this novel DNA, a single transcript was observed
at approximately 1.2 kb. Using Clontech Multiple Tissue Northerns,
the human transcript was apparent in trachea, placenta, testis,
skin, salivary gland, prostate, thyroid with less expression
observed in stomach and pancreas. Zcyto10 was expressed in the
following mouse tissues: kidney, skeletal muscle, salivary gland,
liver and skin.
[0100] The tissue specificity of Zcyto10 expression suggests that
Zcyto10 may be a growth and/or maintenance factor in the trachea
and salivary glands, stomach, pancreas and muscle; and may be
important in local immune responses. Also, the Zcyto10 gene's
location on chromosome 1q32.2 indicates that Zcyto10 is a
growth/differentiation factor or important in regulating the immune
response as IL-10.
[0101] The present invention also provides reagents which will find
use in diagnostic applications. A probe comprising the Zcyto10 DNA
or RNA or a subsequence thereof can be used to determine if the
Zcyto10 gene is present on chromosome 1 or if a mutation has
occurred.
[0102] The present invention also provides reagents with
significant therapeutic value. The Zcyto10 polypeptide (naturally
occurring or recombinant), fragments thereof, antibodies and
anti-idiotypic antibodies thereto, along with compounds identified
as having binding affinity to the Zcyto10 polypeptide, should be
useful in the treatment of conditions associated with abnormal
physiology or development, including abnormal proliferation, e.g.,
cancerous conditions, or degenerative conditions or altered
immunity.
[0103] Antibodies to the Zcyto10 polypeptide can be purified and
then administered to a patient. These reagents can be combined for
therapeutic use with additional active or inert ingredients, e.g.,
in pharmaceutically acceptable carriers or diluents along with
physiologically innocuous stabilizers and excipients. These
combinations can be sterile filtered and placed into dosage forms
as by lyophilization in dosage vials or storage in stabilized
aqueous preparations. This invention also contemplates use of
antibodies, binding fragments thereof or single-chain antibodies of
the antibodies including forms which are not complement
binding.
[0104] The quantities of reagents necessary for effective therapy
will depend upon many different factors, including means of
administration, target site, physiological state of the patient,
and other medications administered. Thus, treatment dosages should
be titrated to optimize safety and efficacy. Typically, dosages
used in vitro may provide useful guidance in the amounts useful for
in vivo administration of these reagents. Animal testing of
effective doses for treatment of particular disorders will provide
further predictive indication of human dosage. Methods for
administration include oral, intravenous, peritoneal,
intramuscular, transdermal or administration into the lung or
trachea in spray form by means or a nebulizer or atomizer
Pharmaceutically acceptable carriers will include water, saline,
buffers to name just a few. Dosage ranges would ordinarily be
expected from 1 .mu.g to 1000 .mu.g per kilogram of body weight per
day. However, the doses by be higher or lower as can be determined
by a medical doctor with ordinary skill in the art. For a complete
discussion of drug formulations and dosage ranges see Remington's
Pharmaceutical Sciences, 18.sup.th Ed., (Mack Publishing Co.,
Easton, Pa., 1996), and Goodman and Gilman's: The Pharmacological
Bases of Therapeutics, 9.sup.th Ed. (Pergamon Press 1996).
Nucleic Acid-Based Therapeutic Treatment
[0105] If a mammal has a mutated or lacks a Zcyto10 gene, the
Zcyto10 gene can be introduced into the cells of the mammal. In one
embodiment, a gene encoding a Zcyto10 polypeptide is introduced in
vivo in a viral vector. Such vectors include an attenuated or
defective DNA virus, such as but not limited to herpes simplex
virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus,
adeno-associated virus (AAV), and the like. Defective viruses,
which entirely or almost entirely lack viral genes, are preferred.
A defective virus is not infective after introduction into a cell.
Use of defective viral vectors allows for administration to cells
in a specific, localized area, without concern that the vector can
infect other cells. Examples of particular vectors include, but are
not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt
et al., Molec. Cell. Neurosci., 2 :320-330 (1991)], an attenuated
adenovirus vector, such as the vector described by
Stratford-Perricaudet et al., J. Clin. Invest., 90 :626-630 (1992),
and a defective adeno-associated virus vector [Samulski et al., J.
Virol., 61:3096-3101 (1987); Samulski et al. J. Virol.,
63:3822-3828 (1989)].
[0106] In another embodiment, the gene can be introduced in a
retroviral vector, e.g., as described in Anderson et al., U.S. Pat.
No. 5,399,346; Mann et al., Cell, 33:153 (1983); Temin et al., U.S.
Pat. No. 4,650,764; Temin et al., U.S. Pat. No. 4,980,289;
Markowitz et al., J. Virol., 62:1120 (1988); Temin et al., U.S.
Pat. No. 5,124,263; International Patent Publication No. WO
95/07358, published Mar. 16, 1995 by Dougherty et al.; and Blood,
82:845 (1993). Alternatively, the vector can be introduced by
lipofection in vivo using liposomes. Synthetic cationic lipids can
be used to prepare liposomes for in vivo transfection of a gene
encoding a marker [Feigner et al., Proc. Natl. Acad. Sci. USA,
84:7413-7417 (1987); see Mackey et al., Proc. Natl. Acad. Sci. USA,
85:8027-8031 (1988)]. The use of lipofection to introduce exogenous
genes into specific organs in vivo has certain practical
advantages. Molecular targeting of liposomes to specific cells
represents one area of benefit. It is clear that directing
transfection to particular cells represents one area of benefit. It
is clear that directing transfection to particular cell types would
be particularly advantageous in a tissue with cellular
heterogeneity, such as the pancreas, liver, kidney, and brain.
Lipids may be chemically coupled to other molecules for the purpose
of targeting. Targeted peptides, e.g., hormones or
neurotransmitters, and proteins such as antibodies, or non-peptide
molecules could be coupled to liposomes chemically. These liposomes
can also be administered in spray form into the lung or trachea by
means of an atomizer or nebulizer.
[0107] It is possible to remove the cells from the body and
introduce the vector as a naked DNA plasmid and then re-implant the
transformed cells into the body. Naked DNA vector for gene therapy
can be introduced into the desired host cells by methods known in
the art, e.g., transfection, electroporation, microinjection,
transduction, cell fusion, DEAE dextran, calcium phosphate
precipitation, use of a gene gun or use of a DNA vector transporter
[see, e.g., Wu et al., J. Biol. Chem., 267:963-967 (1992); Wu et
al., J. Biol. Chem., 263:14621-14624 (1988)].
[0108] Zcyto10 polypeptides can also be used to prepare antibodies
that specifically bind to Zcyto10 polypeptides. These antibodies
can then be used to manufacture anti-idiotypic antibodies. As used
herein, the term "antibodies" includes polyclonal antibodies,
monoclonal antibodies, antigen-binding fragments thereof such as
F(ab').sub.2 and Fab fragments, and the like, including genetically
engineered antibodies. Antibodies are defined to be specifically
binding if they bind to a Zcyto10 polypeptide with a K.sub.a of
greater than or equal to 10.sup.7/M. The affinity of a monoclonal
antibody can be readily determined by one of ordinary skill in the
art (see, for example, Scatchard, ibid.).
[0109] Methods for preparing polyclonal and monoclonal antibodies
are well known in the art (see for example, Sambrook et al.,
Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring
Harbor, N.Y., 1989); and Hurrell, J. G. R., Ed., Monoclonal
Hybridoma Antibodies: Techniques and Applications (CRC Press, Inc.,
Boca Raton, Fla., 1982), which are incorporated herein by
reference). As would be evident to one of ordinary skill in the
art, polyclonal antibodies can be generated from a variety of
warm-blooded animals such as horses, cows, goats, sheep, dogs,
chickens, rabbits, mice, and rats. The immunogenicity of a Zcyto10
polypeptide may be increased through the use of an adjuvant such as
Freund's complete or incomplete adjuvant. A variety of assays known
to those skilled in the art can be utilized to detect antibodies
which specifically bind to Zcyto10 polypeptides. Exemplary assays
are described in detail in Antibodies: A Laboratory Manual, Harlow
and Lane (Eds.), (Cold Spring Harbor Laboratory Press, 1988).
Representative examples of such assays include: concurrent
immunoelectrophoresis, radio-immunoassays,
radio-immunoprecipitations, enzyme-linked immunosorbent assays
(ELISA), dot blot assays, inhibition or competition assays, and
sandwich assays.
[0110] Antibodies to Zcyto10 are may be used for tagging cells that
express the protein, for affinity purification, within diagnostic
assays for determining circulating levels of soluble protein
polypeptides, and as antagonists to block ligand binding and signal
transduction in vitro and in vivo.
[0111] Within another aspect of the present invention there is
provided a pharmaceutical composition comprising purified Zcyto10
polypeptide in combination with a pharmaceutically acceptable
vehicle. Such compositions may be useful for modulating of cell
proliferation, cell differentiation or cytokine production in the
prevention or treatment of conditions characterized by improper
cell proliferation, cell differentiation or cytokine production, as
are further discussed herein. Moreover, Zcyto10 polypeptides of the
present invention may be used in trachea-specific or
tracheobronchial-specific applications, such as in the maintenance
or wound repair of the tracheobronchial epithelium or cells
underlying the same, in regulating mucous production or mucocilary
clearance of debris or in treatment of asthma, bronchitis or other
diseases of the tracheobronchial tract. It is expected that Zcyto10
polypeptide would be administered at a dose ranging between the
same doses used for Zcyto10-Fc construct to doses 100-fold higher,
depending upon the stability of Zcyto10 polypeptide. Therapeutic
doses of Zcyto10 would range from 5 to 5000 .mu.g/kg/day.
[0112] The Zcyto10 polypeptide of the present invention is
expressed highly in salivary gland and trachea and has been found
in saliva by Western blot analysis. The salivary glands synthesize
and secrete a number of proteins having diverse biological
functions. Such proteins facilitate lubrication of the oral cavity
(e.g., mucins and proline-rich proteins), remineralization (e.g.,
statherin and ionic proline-rich proteins) and digestion (e.g.,
amylase, lipase and proteases) and provide anti-microbial (e.g.,
proline-rich proteins, lysozyme, histatins and lactoperoxidase) and
mucosal integrity maintenance (e.g., mucins) capabilities. In
addition, saliva is a rich source of growth factors synthesized by
the salivary glands. For example, saliva is known to contain
epidermal growth factor (EGF), nerve growth factor (NGF),
transforming growth factor-alpha (TGF-.alpha.), transforming growth
factor-beta (TGF-.beta.), insulin, insulin-like growth factors I
and II (IGF-I and IGF-II) and fibroblast growth factor (FGF). See,
for example, Zelles et al., J. Dental. Res. 74(12): 1826-32, 1995.
Synthesis of growth factors by the salivary gland is believed to be
androgen-dependent and to be necessary for the health of the oral
cavity and gastrointestinal tract.
[0113] Thus, Zcyto10 polypeptides, agonists or antagonists thereof
may be therapeutically useful in the regeneration of the
gastrointestinal tract or oral cavity. To verify this presence of
this capability in Zcyto10 polypeptides, agonists or antagonists of
the present invention, such Zcyto10 polypeptides, agonists or
antagonists are evaluated with respect to their ability to break
down starch according to procedures known in the art. Zcyto10
polypeptides, agonists or antagonists thereof may be useful in the
treatment of asthma and other diseases of the tracheobronchial
tract, such as bronchitis and the like, by intervention in the
cross-regulation of Th1 and Th2 lymphocytes, regulation of growth,
differentiation and cytokine production of other inflammatory
cellular mediators, such as eosinophils, mast cells, basophils,
neutrophils and macrophages. Zcyto10 polypeptides, agonists or
antagonists thereof may also modulate muscle tone in the
tracheobronchial tract.
[0114] Zcyto10 polypeptides can also be used to treat a number of
skin conditions either systemically or locally when placed in an
ointment or cream, for example eczema, psoriasis or dry skin
conditions in general or as related skin attentions. Also the
Zcyto10 polypeptide can be directly injected into muscle to treat
muscle atrophy in the elderly, the sick or the bed-ridden.
[0115] Radiation hybrid mapping is a somatic cell genetic technique
developed for constructing high-resolution, contiguous maps of
mammalian chromosomes [Cox et al., Science 250:245-250 (1990)].
Partial or full knowledge of a gene's sequence allows the designing
of PCR primers suitable for use with chromosomal radiation hybrid
mapping panels. Commercially available radiation hybrid mapping
panels which cover the entire human genome, such as the Stanford G3
RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc.,
Huntsville, Ala.), are available. These panels enable rapid, PCR
based, chromosomal localizations and ordering of genes,
sequence-tagged sites (STSs), and other nonpolymorphic- and
polymorphic markers within a region of interest. This includes
establishing directly proportional physical distances between newly
discovered genes of interest and previously mapped markers. The
precise knowledge of a gene's position can be useful in a number of
ways including: 1) determining if a sequence is part of an existing
contig and obtaining additional surrounding genetic sequences in
various forms such as YAC-, BAC- or cDNA clones, 2) providing a
possible candidate gene for an inheritable disease which shows
linkage to the same chromosomal region, and 3) for
cross-referencing model organisms such as mouse which may be
beneficial in helping to determine what function a particular gene
might have.
[0116] The results showed that the Zcyto10 gene maps 889.26
cR.sub.--3000 from the top of the human chromosome 1 linkage group
on the WICGR radiation hybrid map. Proximal and distal framework
markers were D1S504 and WI-9641 (D1S2427), respectively. The use of
the surrounding markers positions the Zcyto10 gene in the 1q32.2
region on the integrated LDB chromosome 1 map (The Genetic Location
Database, University of Southhampton). Numerous genes have been
mapped to the 1q32.2 region of chromosome 1. In particular,
mutations in this region have been found to result in van der Woude
syndrome, associated with malformation of the lower lip that is
sometimes associated with cleft palate. Thus, the Zcyto10 gene,
which is expressed in the salivary gland, may be used in gene
therapy of this syndrome. If a mammal has a mutated or lacks a
Zcyto10 gene, the Zcyto10 gene can be introduced into the cells of
the mammal
[0117] Another aspect of the present invention involves antisense
polynucleotide compositions that are complementary to a segment of
the polynucleotide set forth in SEQ ID NOs: 1, 3 18 and 33. Such
synthetic antisense oligonucleotides are designed to bind to mRNA
encoding Zcyto10 polypeptides and inhibit translation of such mRNA.
Such antisense oligonucleotides are useful to inhibit expression of
Zcyto10 polypeptide-encoding genes in cell culture or in a
subject.
[0118] The present invention also provides reagents which will find
use in diagnostic applications. For example, the Zcyto10 gene, a
probe comprising Zcyto10 DNA or RNA or a subsequence thereof can be
used to determine if the Zcyto10 gene is present on chromosome 1 or
if a mutation has occurred. Detectable chromosomal aberrations at
the Zcyto10 gene locus include but are not limited to aneuploidy,
gene copy number changes, insertions, deletions, restriction site
changes and rearrangements. Such aberrations can be detected using
polynucleotides of the present invention by employing molecular
genetic techniques, such as restriction fragment length
polymorphism (RFLP) analysis, short tandem repeat (STR) analysis
employing PCR techniques, and other genetic linkage analysis
techniques known in the art [Sambrook et al., ibid.; Ausubel, et.
al., ibid.; Marian, A. J., Chest, 108: 255-265, (1995)].
[0119] Those skilled in the art will recognize that the sequences
disclosed in SEQ ID NOs: 2, 4 12, 13, 19, 20, 25, 26, 34 and 35
represent a single alleles of the human and mouse Zcyto10 genes and
polypeptides, and that allelic variation and alternative splicing
are expected to occur. Allelic variants can be cloned by probing
cDNA or genomic libraries from different individuals according to
standard procedures. Allelic variants of the DNA sequence shown in
SEQ ID NOs: 1, 3, 18 and 33 including those containing silent
mutations and those in which mutations result in amino acid
sequence changes, are within the scope of the present
invention.
[0120] The sequence of Zcyto10 has 7 message instability motifs in
the 3' untranslated region at positions 706, 813, 855 and 906 of
SEQ ID NO:1. Treatment of cells expressing Zcyto10 with
cycloheximide can alleviate this message instability. See Shaw, G.
et. al., Cell 46: 659-667 (1986). Furthermore, the AT rich 3'
untranslated region can be genetically altered or removed to
further promote message stability.
[0121] Use of Zcyto10 to Promote Wound Healing
[0122] The data of Example 4 shows that Zcyto10 plays a role in
wound healing. Thus, Zcyto10 can be applied to a wound or a burn to
promote wound healing. Zctyo10 may be administered systemically in
a dosage of from 1 to 100 .mu.g per kilogram weight of the
individual. Zcyto10 may also be applied to a wound by means of a
salve or ointment which contains from 1 ng to 1 mg of Zcyto10 to
gram of salve or ointment. See Remington's Pharmaceutical Sciences,
18.sup.th Ed., (Mack Publishing Co., Easton, Pa., 1996). Zcyto10
should be placed on a cleaned wound on a daily basis until the
wound has healed.
[0123] Use of Zcyto10 to Increase Platelet Count
[0124] As can be seen below in Example 7, we have discovered that
Zcyto10 can be used to increase platelet count. This is especially
important to cancer patients who experience thrombocytopenia due to
chemotherapy or radiation therapy. The Zcyto10 can be administered
therapeutically in with a pharmaceutically acceptable carrier.
[0125] The invention is further illustrated by the following
non-limiting examples.
Example 1
Cloning of Zcyto 10
[0126] The full length sequence of zcyto10.times.1 (the longer
form) and zcyto10.times.2 (the shorter form) was elucidated by
using 3' RACE.TM. and submitting two fragments generated to
sequencing (SEQ ID NO:10 and SEQ ID NO:11), then artificially
splicing together by computer the est sequence shown in SEQ ID NO:5
with the overlapping sequence from the two 3' race fragments.
[0127] An oligo, zc15907 (SEQ ID NO: 6), was designed to the area
just upstream (5') of the putative methionine for zcyto10. Further
downstream, another oligo, zc15906 (SEQ ID NO: 7), was designed to
the area just upstream of the signal sequence cleavage site. These
oligos were used in 3' RACE.TM. reactions on human trachea
MARATHON.TM. cDNA. ZC15907 was used in the primary 3' race reaction
and zc15906 was used in the nested 3' race reaction. The
MARATHON.TM. cDNA was made using the MARATHON.TM. cDNA
Amplification Kit (Clontech, Palo Alto, Calif.) according to the
manufacturer's instructions, starting with human trachea mRNA
purchased from Clontech.
[0128] The PCR reactions were run according to the manufacturer's
instructions in the MARATHON.TM. cDNA Amplification Kit with some
modification in the thermal cycling parameters. The cycling
parameters used in the primary PCR reaction were:
[0129] 94.degree. C. 1 min 30 sec 1.times.
[0130] 94.degree. C. 15 sec 68.degree. C. 1 min 30.times.
[0131] 72.degree. C. 7 min 1.times.
[0132] The cycling parameters used in the nested PCR reaction were:
94.degree. C. 1 min 30 sec 1.times., 94.degree. C. 15 sec
68.degree. C. 1 min 20 sec, 30.times.72.degree. C. 7 min
1.times.
[0133] The resulting products were run out on a 1.2% agarose gel
(Gibco agarose) and two main bands were seen, approximately 80 by
apart. The bands were cut out and gel purified using QIAEX.TM.
resin (Qiagen) according to the manufacturer's instructions. These
fragments were then subjected to sequencing, allowing the full
length sequence of zcyto10 to be discerned.
Example 2
Northern Blot Analysis
[0134] Human multiple tissue blots I, II, III, and a RNA Master Dot
Blot (Clontech) were probed to determine the tissue distribution of
zcyto10. A 45-mer antisense oligo, SEQ ID NO:9, was designed using
the est sequence (SEQ ID NO: 5 by 100-145) and used for the
probe.
[0135] 15 pm of SEQ ID NO: 9 were end labeled with .sup.32P using
T4 polynucleotide kinase (Gibco-BRL). The labeling reaction
contained 2 .mu.l 5.times. forward kinase reaction buffer
(Gibco-BRL), 1 ul T4 kinase, 15 pm SEQ ID NO:9, 1 ul 6000 Ci/mmol
.sup.32P gamma-ATP (Amersham) and water to 10 ul. The reaction was
incubated 30 minutes at 37.degree. C. Unincorporated radioactivity
was removed with a NucTrap.TM. Probe Purification Column
(Stratagene). Multiple tissue northerns and a human RNA Master Blot
(Clontech) were prehybridized at 50.degree. C. three hours in 10 ml
ExpressHyb.TM. (Clontech) which contained 1 mg of salmon sperm DNA
and 0.3 mg human cotl DNA (Gibco.TM.-BRL), both of which were
boiled 3 minutes, iced 2 minutes and then added to the
ExpressHyb.TM.. Hybridization was carried out over night at 50 C.
Initial wash conditions were as follows: 2.times.SSC, 0.1% SDS RT
for 40 minutes with several wash solution changes, then
1.times.SSC, 0.1% SDS at 64.degree. C. (Tm-10) for 30 minutes.
Filters were then exposed to film two days.
[0136] Expression of zcyto10 on the northern blots revealed about a
1.2 kb band in trachea, a faint 1.5 kb band in stomach and fainter
bands of both sizes in pancreas. The dot blots showed the presence
of zcyto10 in trachea, salivary gland, placenta, testis, skin,
prostate gland, adrenal gland and thyroid.
[0137] In the mouse it was found in the kidney, skeletal muscle,
salivary gland, liver and skin.
Example 3
Chromosomal Assignment and Placement of Zcyto10
[0138] Zcyto10 was mapped to chromosome 1 using the commercially
available version of the "Stanford G3 Radiation Hybrid Mapping
Panel" (Research Genetics, Inc., Huntsville, Ala.). The "Stanford
G3 RH Panel" contains PCRable DNAs from each of 83 radiation hybrid
clones of the whole human genome, plus two control DNAs (the RM
donor and the A3 recipient).
[0139] For the mapping of Zcyto10 with the "Stanford G3 RH Panel",
20=|1 reactions were set up in a PCRable 96-well microtiter plate
(Stratagene, La Jolla, Calif.) and used in a "RoboCycler Gradient
96.TM." thermal cycler (Stratagene). Each of the 85 PCR reactions
consisted of 2|110.times. KlenTaq.TM. PCR reaction buffer (CLONTECH
Laboratories, Inc., Palo Alto, Calif.), 1.6|1 dNTPs mix (2.5 mM
each, PERKIN-ELMER, Foster City, Calif.), 1|1 sense primer, SEQ ID
NO: 6, 5' ATT CCT AGC TCC TGT GGT CTC CAG 3', 1|1 antisense primer,
(SEQ ID NO: 8) 5' TCC CAA ATT GAG TGT CTT CAG T 3', 2|1
"RediLoad.TM." (Research Genetics, Inc., Huntsville, Ala.), 0.4|1
50.times. Advantage KlenTaq.TM. Polymerase Mix (Clontech
Laboratories, Inc.), 25 ng of DNA from an individual hybrid clone
or control and x|1 ddH.sub.2O for a total volume of 20|1. The
reactions were overlaid with an equal amount of mineral oil and
sealed. The PCR cycler conditions were as follows: an initial 1
cycle 5 minute denaturation at 95.degree. C., 35 cycles of a 1
minute denaturation at 95.degree. C., 1 minute annealing at
66.degree. C. and 1.5 minute extension at 72.degree. C., followed
by a final 1 cycle extension of 7 minutes at 72.degree. C. The
reactions were separated by electrophoresis on a 2% agarose gel
(Life Technologies, Gaithersburg, Md.).
[0140] The results showed linkage of Zcyto10 to the framework maker
SHGC-36215 with a LOD score of >10 and at a distance of
14.67cR.sub.--10000 from the marker. The use of surrounding markers
positions Zcyto10 in the 1q32.2 region on the integrated LDB
chromosome 1 map (The Genetic Location Database, University of
Southhampton).
Example 4
Use of Zcvot10 to Promote Wound Healing
[0141] Normal adult female Balb/C mice were used in the present
study. They were housed in animal care facilities with a 12-hour
light-dark cycle, given water and laboratory rodent chow ad libitum
during the study. They were individually caged from the day of
surgery.
[0142] On the day of surgery, the animals were anesthetized with
ketamine (Vetalar, Aveco Inc., Ft. Dodge, Iowa) 104 mg/kg plus
Xylazine (Rompun, Mobey Corp., Shawnee, Kans.) 7 mg/kg in sterile
(0.2.mu.-filtered) phosphate buffered saline (PBS) by
intraperitoneal injection. The hair on their backs was clipped and
the skin depilated with NAIR.TM. (Carter-Wallace, New York, N.Y.),
then rinsed with water. 100% aloe vera gel was applied to
counteract the alkaline burn from the NAIR.TM. treatment, then the
animals were placed on circulating water heating pads until the
skin and surrounding fur were dry.
[0143] The animals were then anesthetized with metofane (Pittman
Moore, Mundelein, N.J.) and the depilated dorsum wiped with 70%
ethanol. Four excisions, each of 0.5-cm square were made through
the skin and panniculus carnosus over the paravertebral area at the
level of the thoracic-lumbar vertebrae. The wounds and surrounding
depilated skin were covered with an adhesive, semipermeable
occlusive dressing, BIOCLUSIVE.TM. (Johnson & Johnson,
Arlington, Tex.). The cut edge of the excision was traced through
the BIOCLUSIVE.TM. onto an acetate transparency for later
assessment of closure parameters.
[0144] Control skin and wounded skin at different time points (7
hours, 15 hours and 24 hours) were processed using the Qiagen
RNeasy.TM. Midi kit. Briefly, skin (control and wounded areas) were
weighed and homogenized in appropriate volume of lysis buffer
(RLT). The lysates were spun to remove tissue debris and equal
volume of 70% ethanol was added to the lysates; mixed well and
loaded on column. The samples were spun five minutes and washed
once with 3.8 ml of RW1 buffer, then twice with RPE (2.5 ml each).
The total RNA's were eluted with RNase-free water. The expression
level of the skin samples were measured using real time PCR (Perkin
Elmer ABI Prism.TM. 7700 Sequence Detector).
[0145] The experiment was designed with a non template control, a
set of standard and the skin samples. Mouse kidney total RNA was
use for the standard curve. Three sets of skin total RNA's (25 ng)
were used in this experiment 7 hours (control and wounded); 15
hours (control and wounded), 24 hours (control and wounded). Each
sample was done in triplicate by One Step RT-PCR on the 7700
sequence detector. The in-house forward primer SEQ ID NO:36,
reverse primer SEQ ID NO:37, and the Perkin Elmer's TaqMan.TM.
probe (ZG-7-FAM) were used in the experiment. The condition of the
One Step RT-PCR was as follow: (RT step) 48.degree. C. for 30
minutes, (40 cycles PCR step) 95.degree. C. for 10 minutes,
95.degree. C. for 15 second, 60.degree. C. for 1 minute.
[0146] The expression level of cyto10 in the control skin samples
at 7 hours and 15 hours were comparable at 2.46 ng/ml and 2.61
ng/ml respectively. From the control skin sample at 24 hours, the
expression level of Zcyto10 was zero. The expression level of
Zcyto10 from wounded skin at 7 hours was at 5.17 ng/ml (more than
two fold increase compared to that of the control sample). The
expression level of Zcyto10 from wounded skin at 15 hours was at
14.45 ng/ml (5.5 fold increase compared to that of the control
sample). The expression level of Zcyto10 from wounded skin at 24
hours was at 5.89 ng/ml. A repeat experiment also included a
negative control (yeast tRNA) gave the similar trend and the result
of yeast tRNA was near zero. The result suggested that the
amplification was real and mouse specific.
[0147] These data suggest that Zcyto10 plays a role in the repair
of wounded because the expression level of Zcyto10 from wounded
tissue was up compared to that of the control sample and it
increased and decreased after time. Thus, Zcyto10 can be applied to
wounds to promote wound healing.
Example 5
Transgenic Mice
[0148] Transgenic mice were produced which expressed Zcyto10 either
under the albumin or the metallothionine promoter. At birth,
several of the mice had a shiny appearance and had limited
movement. The skin of these mice was tight and wrinkled; several
also had a whisker-like hair on the lower lip. The nostril and
mouth areas, the extremities and the tail were swollen.
[0149] One transgenic mouse, in which the albumin promoter was used
survived until day three and was severely growth retarded. There
was no ear development and the development of the toes was
diminished. All animals were sacrificed when they were moribund on
days 1, 2 or 3. Tails and liver samples were collected and they
were fixed in situ in 10% neutral formalin embedded in paraffin,
and sectioned at 3 micrometers and stained with H&E. All mice
with this phenotype were transgenic and had low to high expression
of Zcyto10.
[0150] No significant changes were observed in the majority of the
tissues except for the skin. The skin of the Zcyto10 expressing
pups, particularly those mice which had a high expression level of
Zcyto10, tended to be thicker than the non-expressing pups. The
stratum granulosum in these pups appeared to be reduced in
thickness as compared to the non-expressing pups, while the stratum
spinosum was thicker due to increased cell layers and/or increased
cell diameter.
[0151] In addition to the changes in the epidermis, the dermis of
one mouse having medium expression of Zcyto10 was focally
moderately expanded by mucinous material.
Example 6
Purification of Zcyto10 from a Cell Culture Medium
[0152] Zcyto10 produced by CHO cells was isolated from the cell
culture medium using a two step method involving a cation exchange
chromatography and size exclusion chromatography.
Cation Exchange Chromatography Step.
Materials Used
[0153] 2.2 cm diameter (D).times.6 cm height (H) column (AMICON)
packed with a SP-650M cation exchange resin, which is a
TOYOPEARL.TM. ion exchange resin having covalently bonded
sulfopropyl (SP) groups.
[0154] Fifteen (15) liters of culture medium from baby hamster
kidney (BHK) cells which had been transfected with a Zcyto 10
containing plasmid was collected. The pH of the culture medium was
adjusted to pH5 with 2N HCl. The above-described packed column was
equilibrated with 50 mM sodium acetate, NaAc, pH5.0. The culture
medium was loaded onto the column at the rate of 20 column-volumes
(cv)/hr at approximately 8 ml/min. When the loading was done the
column was washed with 10 cv of 50 mM NaAc, pH5.0. The material in
the column was then eluted with 20 cv of NaCl gradient in 50 mM
NaAc, pH 5.0. The NaCl gradient ranged from 0 to 0.5 M NaCl. This
concentrated the material in the culture medium from 15 liters to
170 ml.
[0155] The resultant 170 ml harvest was further concentrated to
about 5 ml with a spin 5 thousand cut-off centrifugal concentrator
(Millipore, Inc., Bedford, Mass.).
Size Exclusion (S-100) Gel Filtration Step
Materials Used.
[0156] Column 1.6 cm (diameter) X 93 cm (height)
[0157] S-100 gel (Pharmacia, Piscataway, N.J.)
[0158] The 5 ml harvest was then loaded onto the above-described
column containing S-100 gel. The column had been equilibrated with
5.times. phosphate buffered saline to bring the pH of the column to
about 7.0. Zcyto10 was isolated from the contaminants by using
1.times.PBS at a flow rate of 1.5 ml/min. Fractions were collected
at 2 ml increments. The Zcyto10 polypeptide came out in fractions
52-64 at about 90 minutes after the elution had been initiated as
determined by sodium dodecyl sulfate (SDS) polyacrylamide gel
electrophoresis which were stained with Coomassie Blue. The gel
revealed one band at the predicted molecular weight of about 14
kDa.
Example 7
Cloning of Murine Zcyto10
[0159] PCR primers 5' MARATHON RACE.TM. (Clontech, Palo Alto,
Calif.) primer set SEQ ID NO: 38 attached to MARATHON.TM. AP1
adapter, nested with SEQ ID NO:39 attached to AP2 MARATHON.TM.
adapter, with 3' MARATHON RACE.TM. primer set SEQ ID NO: 40
attached to MARATHON RACE.TM. AP1 adapter, nested with SEQ ID NO:41
attached to MARATHON RACE.TM. AP2 adapter and 5' and 3' race was
performed on mouse skin MARATHON RACE.TM. cDNA. Several fragments
were from these reactions were gel purified and sequenced, allowing
the elucidation of the full length coding sequence of the mouse
zcyto10, plus some 5' and 3' UTR sequence. Two murine Zcyto10
variants were discovered, namely SEQ ID NOs: 18 and 19 and SEQ ID
NOs: 33 and 34. The clones were amplified by PCR using primers SEQ
ID NOs:42 and 43.
Example 8
Adenovirus Administration of Zcyto10 to Normal Mice
[0160] Zcyto10 was administered by adenovirus containing the
Zcyto10 gene. There were three groups of mice as described below.
The adenovirus was injected intravenously into C57B1/6 male and
female mice. All mice received bromodeoxyuridine (BrdU) in their
drinking water 3 days before sacrifice. This allowed for detection
of cell proliferation by histologic methods. Parameters measured
included weight change, complete blood counts, serum chemistries,
histology, organ weights and cell proliferation by BrdU.
[0161] Experimental Design [0162] Group 1 Zcyto10.times.1 (SEQ ID
NO: 18)/pAC-CMV/AdV [0163] 1.times.10.sup.11 particles/dose [0164]
(9 females, 9 males sacrificed on day 21) [0165] (2 females, 2
males sacrificed on day 11) [0166] total number=22 mice. [0167]
Group 2 null CMV/AdV control [0168] 1.times.10.sup.11
particles/dose [0169] (10 females, 10 males sacrificed on day 21)
[0170] (2 females, 2 males sacrificed on day 11) [0171] total
number=24 mice. [0172] Group 3 no treatment [0173] (5 females, 5
males) [0174] total number=10.
[0175] Results
[0176] The most striking effect was a significant increase in
platelet count which was observed in male and female mice treated
with Zcyto10-adenovirus compared to empty adenovirus control. This
was accompanied in male mice by a decrease hematocrit and increased
spleen and liver weight. The thymus weight was decreased in males
also. In contrast Zcyto10-adenovirus treated female mice showed
significantly increased white blood cell counts which were
consisted primarily of increased lymphocyte and neutrophil counts
compared to the empty virus control.
[0177] These results suggest that hematopoiesis is effected by
Zcyto10 treatment, but except for the increased platelet count
which effected both sexes, other effects are sex specific. Other
effects included the following.
[0178] Female glucose levels were lower in treated groups while
those of the males showed no significant change.
[0179] Blood Urea Nitrogen (BUN) was higher in both male and female
treated groups.
[0180] Female alkaline phosphatase was higher in the treated group
while the males showed no significant change.
[0181] The platelet counts were higher in both male and female
treated groups.
[0182] Female total white blood counts (WBC) were higher in the
treated groups while the males showed no significant change.
Sequence CWU 1
1
461926DNAHomo sapiensCDS(45)..(572) 1ctttgaattc ctagctcctg
tggtctccag atttcaggcc taag atg aaa gcc tct 56 Met Lys Ala Ser 1 agt
ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act 104Ser
Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr 5 10 15
20 cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc
152Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala
25 30 35 aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cgg
ggc agt 200Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg
Gly Ser 40 45 50 gtg caa gcc aaa gat gga aac att gac atc aga atc
tta agg agg act 248Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile
Leu Arg Arg Thr 55 60 65 gag tct ttg caa gac aca aag cct gcg aat
cga tgc tgc ctc ctg cgc 296Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn
Arg Cys Cys Leu Leu Arg 70 75 80 cat ttg cta aga ctc tat ctg gac
agg gta ttt aaa aac tac cag acc 344His Leu Leu Arg Leu Tyr Leu Asp
Arg Val Phe Lys Asn Tyr Gln Thr 85 90 95 100 cct gac cat tat act
ctc cgg aag atc agc agc ctc gcc aat tcc ttt 392Pro Asp His Tyr Thr
Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe 105 110 115 ctt acc atc
aag aag gac ctc cgg ctc tgt cat gcc cac atg aca tgc 440Leu Thr Ile
Lys Lys Asp Leu Arg Leu Cys His Ala His Met Thr Cys 120 125 130 cat
tgt ggg gag gaa gca atg aag aaa tac agc cag att ctg agt cac 488His
Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His 135 140
145 ttt gaa aag ctg gaa cct cag gca gca gtt gtg aag gct ttg ggg gaa
536Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu
150 155 160 cta gac att ctt ctg caa tgg atg gag gag aca gaa
taggaggaaa 582Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu 165
170 175 gtgatgctgc tgctaagaat attcgaggtc aagagctcca gtcttcaata
cctgcagagg 642aggcatgacc ccaaaccacc atctctttac tgtactagtc
ttgtgctggt cacagtgtat 702cttatttatg cattacttgc ttccttgcat
gattgtcttt atgcatcccc aatcttaatt 762gagaccatac ttgtataaga
tttttgtaat atctttctgc tattggatat atttattagt 822taatatattt
atttattttt tgctattaat gtatttaatt ttttacttgg gcatgaaact
882ttaaaaaaaa ttcacaagat tatatttata acctgactag agca 9262176PRTHomo
sapiens 2Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala
Phe Tyr 1 5 10 15 Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu
Asn Leu Gly Ser 20 25 30 Cys Val Ile Ala Thr Asn Leu Gln Glu Ile
Arg Asn Gly Phe Ser Asp 35 40 45 Ile Arg Gly Ser Val Gln Ala Lys
Asp Gly Asn Ile Asp Ile Arg Ile 50 55 60 Leu Arg Arg Thr Glu Ser
Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys 65 70 75 80 Cys Leu Leu Arg
His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys 85 90 95 Asn Tyr
Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu 100 105 110
Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala 115
120 125 His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser
Gln 130 135 140 Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala
Val Val Lys 145 150 155 160 Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln
Trp Met Glu Glu Thr Glu 165 170 175 3793DNAHomo
sapiensCDS(45)..(497) 3ctttgaattc ctagctcctg tggtctccag atttcaggcc
taag atg aaa gcc tct 56 Met Lys Ala Ser 1 agt ctt gcc ttc agc ctt
ctc tct gct gcg ttt tat ctc cta tgg act 104Ser Leu Ala Phe Ser Leu
Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr 5 10 15 20 cct tcc act gga
ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc 152Pro Ser Thr Gly
Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala 25 30 35 aca aac
ctt cag gaa ata cga aat gga ttt tct gac ata cgg ggc agt 200Thr Asn
Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser 40 45 50
gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act
248Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr
55 60 65 gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc
ctg cgc 296Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu
Leu Arg 70 75 80 cat ttg cta aga ctc tat ctg gac agg gta ttt aaa
aac tac cag acc 344His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys
Asn Tyr Gln Thr 85 90 95 100 cct gac cat tat act ctc cgg aag atc
agc agc ctc gcc aat tcc ttt 392Pro Asp His Tyr Thr Leu Arg Lys Ile
Ser Ser Leu Ala Asn Ser Phe 105 110 115 ctt acc atc aag aag gac ctc
cgg ctc tgt ctg gaa cct cag gca gca 440Leu Thr Ile Lys Lys Asp Leu
Arg Leu Cys Leu Glu Pro Gln Ala Ala 120 125 130 gtt gtg aag gct ttg
ggg gaa cta gac att ctt ctg caa tgg atg gag 488Val Val Lys Ala Leu
Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu 135 140 145 gag aca gaa
taggaggaaa gtgatgctgc tgctaagaat attcgaggtc 537Glu Thr Glu 150
aagagctcca gtcttcaata cctgcagagg aggcatgacc ccaaaccacc atctctttac
597tgtactagtc ttgtgctggt cacagtgtat cttatttatg cattacttgc
ttccttgcat 657gattgtcttt atgcatcccc aatcttaatt gagaccatac
ttgtataaga tttttgtaat 717atctttctgc tattggatat atttattagt
taatatattt atttattttt tgctattaat 777gtatttaatt ttttac
7934151PRTHomo sapiens 4Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu
Ser Ala Ala Phe Tyr 1 5 10 15 Leu Leu Trp Thr Pro Ser Thr Gly Leu
Lys Thr Leu Asn Leu Gly Ser 20 25 30 Cys Val Ile Ala Thr Asn Leu
Gln Glu Ile Arg Asn Gly Phe Ser Asp 35 40 45 Ile Arg Gly Ser Val
Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile 50 55 60 Leu Arg Arg
Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys 65 70 75 80 Cys
Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys 85 90
95 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu
100 105 110 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys
Leu Glu 115 120 125 Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu
Asp Ile Leu Leu 130 135 140 Gln Trp Met Glu Glu Thr Glu 145 150
5253DNAHomo sapiens 5ctttgaattc ctagctcctg tggtctccag atttcaggcc
taagatgaaa gcctctagtc 60ttgccttcag ccttctctct gctgcgtttt atctcctatg
gactccttcc actggactga 120agacactcaa tttgggaagc tgtgtgatcg
ccacaaacct tcaggaaata cgaaatggat 180tttctgagat acggggcagt
gtgcaagcca aagatggaaa cattgacatc agaatcttaa 240ggaggactga gtc
253624DNAHomo sapiens 6attcctagct cctgtggtct ccag 24725DNAHomo
sapiens 7ctctgctgcg ttttatctcc tatgg 25822DNAHomo sapiens
8tcccaaattg agtgtcttca gt 22945DNAHomo sapiens 9cacagcttcc
caaattgagt gtcttcagtc cagtggaagg agtcc 4510747DNAHomo sapiens
10ttttctgaca tacggggcag tgtgcaagcc aaagatggaa acattgacat cagaatctta
60aggaggactg agtctttgca agacacaaag cctgcgaatc gatgctgcct cctgcgccat
120ttgctaagac tctatctgga cagggtattt aaaaactacc agacccctga
ccattatact 180ctccggaaga tcagcagcct cgccaattcc tttcttacca
tcaagaagga cctccggctc 240tgtcatgccc acatgacatg ccattgtggg
gaggaagcaa tgaagaaata cagccagatt 300ctgagtcact ttgaaaagct
ggaacctcag gcagcagttg tgaaggcttt gggggaacta 360gacattcttc
tgcaatggat ggaggagaca gaataggagg aaagtgatgc tgctgctaag
420aatattcgag gtcaagagct ccagtcttca atacctgcag aggaggcatg
accccaaacc 480accatctctt tactgtacta gtcttgtgct ggtcacagtg
tatcttattt atgcattact 540tgcttccttg catgattgtc tttatgcatc
cccaatctta attgagacca tacttgtata 600agatttttgt aatatctttc
tgctattgga tatatttatt agttaatata tttatttatt 660ttttgctatt
aatgtattta attttttact tgggcatgaa actttaaaaa aaattcacaa
720gattatattt ataacctgac tagagca 74711614DNAHomo sapiens
11ttttctgaca tacggggcag tgtgcaagcc aaagatggaa acattgacat cagaatctta
60aggaggactg agtctttgca agacacaaag cctgcgaatc gatgctgcct cctgcgccat
120ttgctaagac tctatctgga cagggtattt aaaaactacc agacccctga
ccattatact 180ctccggaaga tcagcagcct cgccaattcc tttcttacca
tcaagaagga cctccggctc 240tgtctggaac ctcaggcagc agttgtgaag
gctttggggg aactagacat tcttctgcaa 300tggatggagg agacagaata
ggaggaaagt gatgctgctg ctaagaatat tcgaggtcaa 360gagctccagt
cttcaatacc tgcagaggag gcatgacccc aaaccaccat ctctttactg
420tactagtctt gtgctggtca cagtgtatct tatttatgca ttacttgctt
ccttgcatga 480ttgtctttat gcatccccaa tcttaattga gaccatactt
gtataagatt tttgtaatat 540ctttctgcta ttggatatat ttattagtta
atatatttat ttattttttg ctattaatgt 600atttaatttt ttac 61412152PRTHomo
sapiens 12Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala Thr Asn
Leu Gln 1 5 10 15 Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser
Val Gln Ala Lys 20 25 30 Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg
Arg Thr Glu Ser Leu Gln 35 40 45 Asp Thr Lys Pro Ala Asn Arg Cys
Cys Leu Leu Arg His Leu Leu Arg 50 55 60 Leu Tyr Leu Asp Arg Val
Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr 65 70 75 80 Thr Leu Arg Lys
Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys 85 90 95 Lys Asp
Leu Arg Leu Cys His Ala His Met Thr Cys His Cys Gly Glu 100 105 110
Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe Glu Lys Leu 115
120 125 Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile
Leu 130 135 140 Leu Gln Trp Met Glu Glu Thr Glu 145 150
13127PRTHomo sapiens 13Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile
Ala Thr Asn Leu Gln 1 5 10 15 Glu Ile Arg Asn Gly Phe Ser Asp Ile
Arg Gly Ser Val Gln Ala Lys 20 25 30 Asp Gly Asn Ile Asp Ile Arg
Ile Leu Arg Arg Thr Glu Ser Leu Gln 35 40 45 Asp Thr Lys Pro Ala
Asn Arg Cys Cys Leu Leu Arg His Leu Leu Arg 50 55 60 Leu Tyr Leu
Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr 65 70 75 80 Thr
Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys 85 90
95 Lys Asp Leu Arg Leu Cys Leu Glu Pro Gln Ala Ala Val Val Lys Ala
100 105 110 Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr
Glu 115 120 125 1415PRTHomo sapiens 14Ile Ala Thr Asn Leu Gln Glu
Ile Arg Asn Gly Phe Ser Asp Ile 1 5 10 15 1515PRTHomo sapiens 15Leu
Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr 1 5 10 15
1615PRTHomo sapiens 16Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp
Leu Arg Leu Cys 1 5 10 15 1715PRTHomo sapiens 17Val Val Lys Ala Leu
Gly Glu Leu Asp Ile Leu Leu Gln Trp Met 1 5 10 15 18824DNAMus
musculusCDS(71)..(598) 18tgggagacat cgatagccct gattgatctc
tttgaatttt cgcttctggt ctccaggatc 60taggtgtaag atg aaa ggc ttt ggt
ctt gcc ttt gga ctg ttc tcc gct 109 Met Lys Gly Phe Gly Leu Ala Phe
Gly Leu Phe Ser Ala 1 5 10 gtg ggt ttt ctt ctc tgg act cct tta act
ggg ctc aag acc ctc cat 157Val Gly Phe Leu Leu Trp Thr Pro Leu Thr
Gly Leu Lys Thr Leu His 15 20 25 ttg gga agc tgt gtg att act gca
aac cta cag gca ata caa aag gaa 205Leu Gly Ser Cys Val Ile Thr Ala
Asn Leu Gln Ala Ile Gln Lys Glu 30 35 40 45 ttt tct gag att cgg gat
agt gtg caa gct gaa gat aca aat att gac 253Phe Ser Glu Ile Arg Asp
Ser Val Gln Ala Glu Asp Thr Asn Ile Asp 50 55 60 atc aga att tta
agg acg act gag tct ttg aaa gac ata aag tct ttg 301Ile Arg Ile Leu
Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu 65 70 75 gat agg
tgc tgc ttc ctt cgt cat cta gtg aga ttc tat ctg gac agg 349Asp Arg
Cys Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg 80 85 90
gta ttc aaa gtc tac cag acc cct gac cac cat acc ctg aga aag atc
397Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile
95 100 105 agc agc ctc gcc aac tcc ttt ctt atc atc aag aag gac ctc
tca gtc 445Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu
Ser Val 110 115 120 125 tgt cat tct cac atg gca tgt cat tgt ggg gaa
gaa gca atg gag aaa 493Cys His Ser His Met Ala Cys His Cys Gly Glu
Glu Ala Met Glu Lys 130 135 140 tac aac caa att ctg agt cac ttc ata
gag ttg gaa ctt cag gca gcg 541Tyr Asn Gln Ile Leu Ser His Phe Ile
Glu Leu Glu Leu Gln Ala Ala 145 150 155 gtg gta aag gct ttg gga gaa
cta ggc att ctt ctg aga tgg atg gag 589Val Val Lys Ala Leu Gly Glu
Leu Gly Ile Leu Leu Arg Trp Met Glu 160 165 170 gag atg cta
tagatgaaag tggagaggct gctgagaaca ctcctgtcca 638Glu Met Leu 175
agaatctcag acctcagcac catgaagaca tggccccagg tgctggcatt tctactcaag
698agttccagtc ctcagcacca cgaagatggc ctcaaaccac cacccctttg
tgatataact 758tagtgctagc tatgtgtata ttatttctac attattggct
cccttatgtg aatgccttca 818tgtgtc 82419176PRTMus musculus 19Met Lys
Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe 1 5 10 15
Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser 20
25 30 Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser
Glu 35 40 45 Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp
Ile Arg Ile 50 55 60 Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys
Ser Leu Asp Arg Cys 65 70 75 80 Cys Phe Leu Arg His Leu Val Arg Phe
Tyr Leu Asp Arg Val Phe Lys 85 90 95 Val Tyr Gln Thr Pro Asp His
His Thr Leu Arg Lys Ile Ser Ser Leu 100 105 110 Ala Asn Ser Phe Leu
Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser 115 120 125 His Met Ala
Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln 130 135 140 Ile
Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys 145 150
155 160 Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met
Leu 165 170
175 20152PRTMus musculus 20Leu Lys Thr Leu His Leu Gly Ser Cys Val
Ile Thr Ala Asn Leu Gln 1 5 10 15 Ala Ile Gln Lys Glu Phe Ser Glu
Ile Arg Asp Ser Val Gln Ala Glu 20 25 30 Asp Thr Asn Ile Asp Ile
Arg Ile Leu Arg Thr Thr Glu Ser Leu Lys 35 40 45 Asp Ile Lys Ser
Leu Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg 50 55 60 Phe Tyr
Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His 65 70 75 80
Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys 85
90 95 Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His Cys Gly
Glu 100 105 110 Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser His Phe
Ile Glu Leu 115 120 125 Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly
Glu Leu Gly Ile Leu 130 135 140 Leu Arg Trp Met Glu Glu Met Leu 145
150 2116PRTMus musculus 21Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys
Glu Phe Ser Glu Ile Arg 1 5 10 15 2215PRTMus musculus 22Leu Asp Arg
Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr 1 5 10 15
2315PRTMus musculus 23Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp
Leu Ser Val Cys 1 5 10 15 2415PRTMus musculus 24Val Val Lys Ala Leu
Gly Glu Leu Gly Ile Leu Leu Arg Trp Met 1 5 10 15 25144PRTMus
musculus 25Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe
Ser Glu 1 5 10 15 Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile
Asp Ile Arg Ile 20 25 30 Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile
Lys Ser Leu Asp Arg Cys 35 40 45 Cys Phe Leu Arg His Leu Val Arg
Phe Tyr Leu Asp Arg Val Phe Lys 50 55 60 Val Tyr Gln Thr Pro Asp
His His Thr Leu Arg Lys Ile Ser Ser Leu 65 70 75 80 Ala Asn Ser Phe
Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser 85 90 95 His Met
Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln 100 105 110
Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys 115
120 125 Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met
Leu 130 135 140 26144PRTHomo sapiens 26Cys Val Ile Ala Asn Thr Leu
Gln Glu Ile Arg Asn Gly Phe Ser Asp 1 5 10 15 Ile Arg Gly Ser Val
Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile 20 25 30 Leu Arg Arg
Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys 35 40 45 Cys
Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys 50 55
60 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu
65 70 75 80 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys
His Ala 85 90 95 His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys
Lys Tyr Ser Gln 100 105 110 Ile Leu Ser His Phe Glu Lys Leu Glu Pro
Gln Ala Ala Val Val Lys 115 120 125 Ala Leu Gly Glu Leu Asp Ile Leu
Leu Gln Trp Met Glu Glu Thr Glu 130 135 140 2738PRTHomo sapiens
27Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe 1
5 10 15 Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu
Leu 20 25 30 Asp Ile Leu Leu Gln Trp 35 2871PRTHomo sapiens 28Ile
Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg 1 5 10
15 Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg
20 25 30 Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys
Cys Leu 35 40 45 Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val
Phe Lys Asn Tyr 50 55 60 Gln Thr Pro Asp His Tyr Thr 65 70
2992PRTHomo sapiens 29Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly
Phe Ser Asp Ile Arg 1 5 10 15 Gly Ser Val Gln Ala Lys Asp Gly Asn
Ile Asp Ile Arg Ile Leu Arg 20 25 30 Arg Thr Glu Ser Leu Gln Asp
Thr Lys Pro Ala Asn Arg Cys Cys Leu 35 40 45 Leu Arg His Leu Leu
Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr 50 55 60 Gln Thr Pro
Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn 65 70 75 80 Ser
Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys 85 90 3082PRTHomo
sapiens 30Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr
Thr Leu 1 5 10 15 Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr
Ile Lys Lys Asp 20 25 30 Leu Arg Leu Cys His Ala His Met Thr Cys
His Cys Gly Glu Glu Ala 35 40 45 Met Lys Lys Tyr Ser Gln Ile Leu
Ser His Phe Glu Lys Leu Glu Pro 50 55 60 Gln Ala Ala Val Val Lys
Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln 65 70 75 80 Trp Met
3136PRTHomo sapiens 31Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro
Asp His Tyr Thr Leu 1 5 10 15 Arg Lys Ile Ser Ser Leu Ala Asn Ser
Phe Leu Thr Ile Lys Lys Asp 20 25 30 Leu Arg Leu Cys 35 3261PRTHomo
sapiens 32Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu
Cys His 1 5 10 15 Ala His Met Thr Cys His Cys Gly Glu Glu Ala Met
Lys Lys Tyr Ser 20 25 30 Gln Ile Leu Ser His Phe Glu Lys Leu Glu
Pro Gln Ala Ala Val Val 35 40 45 Lys Ala Leu Gly Glu Leu Asp Ile
Leu Leu Gln Trp Met 50 55 60 33756DNAMus musculusCDS(71)..(532)
33tgggagacat cgatagccct gattgatctc tttgaatttt cgcttctggt ctccaggatc
60taggtgtaag atg aaa ggc ttt ggt ctt gcc ttt gga ctg ttc tcc gct
109 Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala 1 5 10 gtg
ggt ttt ctt ctc tgg act cct tta act ggg ctc aag acc ctc cat 157Val
Gly Phe Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His 15 20
25 ttg gga agc tgt gtg att act gca aac cta cag gca ata caa aag gaa
205Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu
30 35 40 45 ttt tct gag att cgg gat agt gtg tct ttg gat agg tgc tgc
ttc ctt 253Phe Ser Glu Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys
Phe Leu 50 55 60 cgt cat cta gtg aga ttc tat ctg gac agg gta ttc
aaa gtc tac cag 301Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe
Lys Val Tyr Gln 65 70 75 acc cct gac cac cat acc ctg aga aag atc
agc agc ctc gcc aac tcc 349Thr Pro Asp His His Thr Leu Arg Lys Ile
Ser Ser Leu Ala Asn Ser 80 85 90 ttt ctt atc atc aag aag gac ctc
tca gtc tgt cat tct cac atg gca 397Phe Leu Ile Ile Lys Lys Asp Leu
Ser Val Cys His Ser His Met Ala 95 100 105 tgt cat tgt ggg gaa gaa
gca atg gag aaa tac aac caa att ctg agt 445Cys His Cys Gly Glu Glu
Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser 110 115 120 125 cac ttc ata
gag ttg gaa ctt cag gca gcg gtg gta aag gct ttg gga 493His Phe Ile
Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly 130 135 140 gaa
cta ggc att ctt ctg aga tgg atg gag gag atg cta tagatgaaag 542Glu
Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu 145 150 tggataggct
gctgagaaca ctcctgtcca agaatctcag acctcagcac catgaagaca
602tggccccagg tgctggcatt tctactcaag agttccagtc ctcagcacca
cgaagatggc 662ctcaaaccac cacccctttg tgatataact tagtgctagc
tatgtgtata ttatttctac 722attattggct cccttatgtg aatgccttca tgtg
75634154PRTMus musculus 34Met Lys Gly Phe Gly Leu Ala Phe Gly Leu
Phe Ser Ala Val Gly Phe 1 5 10 15 Leu Leu Trp Thr Pro Leu Thr Gly
Leu Lys Thr Leu His Leu Gly Ser 20 25 30 Cys Val Ile Thr Ala Asn
Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu 35 40 45 Ile Arg Asp Ser
Val Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu 50 55 60 Val Arg
Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp 65 70 75 80
His His Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Ile 85
90 95 Ile Lys Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His
Cys 100 105 110 Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser
His Phe Ile 115 120 125 Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala
Leu Gly Glu Leu Gly 130 135 140 Ile Leu Leu Arg Trp Met Glu Glu Met
Leu 145 150 35130PRTMus musculus 35Leu Lys Thr Leu His Leu Gly Ser
Cys Val Ile Thr Ala Asn Leu Gln 1 5 10 15 Ala Ile Gln Lys Glu Phe
Ser Glu Ile Arg Asp Ser Val Ser Leu Asp 20 25 30 Arg Cys Cys Phe
Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val 35 40 45 Phe Lys
Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser 50 55 60
Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys 65
70 75 80 His Ser His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu
Lys Tyr 85 90 95 Asn Gln Ile Leu Ser His Phe Ile Glu Leu Glu Leu
Gln Ala Ala Val 100 105 110 Val Lys Ala Leu Gly Glu Leu Gly Ile Leu
Leu Arg Trp Met Glu Glu 115 120 125 Met Leu 130 3627DNAHomo sapiens
36agattctatc tggacagggt attcaaa 273717DNAHomo sapiens 37gcgaggctga
tctttct 173825DNAMus musculus 38tggcgaggct gctgatcttt ctcag
253925DNAMus musculus 39ctttatgtct ttcaaagact cagtc 254026DNAMus
musculus 40catcagaatt ttaaggacga ctgagt 264125DNAMus musculus
41ggtggtcagg ggtctggtag acttt 254223DNAMus musculus 42ggtgcatatt
cctggtggct aga 234325DNAMus musculus 43attgcagtgt aagggaatac agaga
254412DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotide 44atggcttagc tt 124512DNAArtificial
SequenceDescription of Artificial Sequence Synthetic
oligonucleotide 45tagcttgagt ct 124612DNAArtificial
SequenceDescription of Artificial Sequence Synthetic
oligonucleotide 46gtcgactacc ga 12
* * * * *